Aryl-N-aryl derivatives for treating a RNA virus infection

Abstract

The present invention relates to a compound of formula (I) wherein X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group, X2 represents a -O- group, a-CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, a -NH-CO- group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms or a -SO2-NH- group, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or a -CR1R2R3 group or alternatively X2-Y2 represents a group -CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. The present invention further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Description

The present invention relates to compounds useful for preventing and / or treating a RNA virus infection, and most preferably a RNA virus infection caused by RNA viruses 5 belonging to group IV or V of the Baltimore classification. The present invention further relates to some new compounds, in particular useful for preventing and / or treating a RNA virus infection, and most preferably a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. 10              It further relates to the pharmaceutical compositions containing said new compounds and to the chemical synthesis processes for obtaining them. BACKGROUND Viruses are one of the major causes of diseases around the world. Viruses are 15 generally defined as small, non-living, infectious agents that replicate only within living cells, as they do not possess a completely autonomous replication mechanism. Although diverse in shape and size, they typically consist of a virus particle (known as a “virion”), made from a protein coat which comprises at least one nucleic acid molecule and optionally, depending on the type of virus, one or more proteins or nucleoproteins. 20              Because viruses do not possess a completely autonomous replication mechanism, they must necessarily rely on the machinery and metabolism of the infected cell or host, in order to replicate and produce multiple copies of themselves. Even though their replication cycle varies greatly between species, it is generally recognized that the life cycle of viruses includes six basic steps: attachment, penetration, 25 uncoating, replication, assembly and release. Depending on the nature of the targeted virus, therapeutic molecules have been designed which may interfere with one or more of those mechanisms. Among those, the replication step involves not only the multiplication of the viral genome, but also the synthesis of viral messenger RNA, of viral protein, and the 30 modulation of the transcription or translation machinery of the host. However, it is also clear that the type of genome (single-stranded, double-stranded, RNA, DNA...) characterizes dramatically this replication step. For instance, most DNA viruses assemble in the nucleus 2019300101   30 Mar 2026 while most RNA viruses develop solely in the cytoplasm. Also, there is increasing evidence that single-stranded RNA viruses such as Influenza use the host RNA splicing and maturation machinery. Accordingly, and considering the implications of a given type of genome in the 5 replication step, the Baltimore classification of viruses was developed. This classification clusters viruses into families (or “groups”) depending on their type of genome. The present virus classification, as in 2018, comprises seven different groups: - Group I: double-stranded DNA viruses (dsDNA); - Group II: single-stranded DNA viruses (ssDNA); 10      - Group III: double-stranded RNA viruses (dsRNA); - Group IV: (+)strand or sense RNA viruses ((+)ssRNA); - Group V: (-)strand or antisense RNA viruses ((-)ssRNA); - Group VI: single-stranded RNA viruses having DNA intermediates (ssRNA-RT); - Group VII: double-stranded DNA viruses having RNA intermediates (dsDNA-RT). 15 According to that classification, viruses belonging to the Group VI are not, stricto sensu, RNA viruses. For the same reasons, viruses belonging to the Group VII are not, stricto sensu, DNA viruses. One well-studied example of a virus family belonging to the Group VI is the family Retroviridae (retrovirus) which includes HIV. One well-studied 20 example of a virus family belonging to the Group VII is the family Hepadnaviridae which includes the Hepatitis B virus (HBV). As a representative of viruses pertaining to group IV one may cite the Picornaviruses (which is a family of viruses that includes well-known viruses like Hepatitis 25 A virus, enteroviruses, rhinoviruses, poliovirus, and foot-and-mouth virus), SARS virus, Hepatitis C virus, yellow fever virus, and rubella virus. The Togaviridae family also pertains to the group IV and a known genus thereof is alphavirus, encompassing the Chikungunya virus. Flaviridae is also a family pertaining to group IV, encompassing a famous virus transmitted by mosquitoes, i.e. the Dengue virus. 30              As a representative of viruses pertaining to group V one may cite the Filoviridae virus family encompassing the Ebola virus, the Paramyxoviridae family encompassing the 2019300101   30 Mar 2026 Respiratory Syncytial virus (RSV), the Rhabdoviridae family, the Orthomyxoviridae family encompassing the Influenzavirus A, Influenzavirus B and Influenzavirus C. Groups within the virus families particularly focused in the framework of the present invention are the ones encompassing RNA viruses, especially single-stranded RNA 5 viruses, and more specifically RNA viruses belonging to group IV and group V of the Baltimore classification. There are few cures for diseases caused by RNA virus infections, in particular single-stranded RNA viruses, and more specifically RNA virus infections from viruses belonging to group IV and V of the Baltimore classification. Treatment is focused on 10 relieving the symptoms. Therefore, there is still a need to identify new antiviral drugs to treat RNA virus infections, such as RNA virus infection from group IV and V, in particular small chemical molecules. DEFINITIONS 15               As used herein, the term "patient" refers to either an animal, such as a valuable animal for breeding, company or preservation purposes, or preferably a human or a human child, which is afflicted with, or has the potential to be afflicted with, one or more diseases and conditions described herein. In particular, as used in the present application, the term “patient” refers to a 20 mammal such as a rodent, cat, dog, primate or human, preferably said subject is a human and also extends to birds. The identification of those patients who are in need of treatment of herein-described diseases and conditions is well within the ability and knowledge of one skilled in the art. A veterinarian or a physician skilled in the art can readily identify, by the use of clinical tests, 25 physical examination, medical / family history or biological and diagnostic tests, those patients who are in need of such treatment. In the context of the invention, the term “treating” or “treatment”, as used herein, means reversing, alleviating, inhibiting the progress of, or preventing the disease resulting from RNA virus infection, and more particularly RNA virus infection from group IV or V, or one 30 or more symptoms of such disease. As used herein, an "effective amount" refers to an amount of a compound of the present invention which is effective in preventing, reducing, eliminating, treating or controlling 2019300101   30 Mar 2026 the symptoms of the herein-described diseases and conditions, i.e. RNA virus infection, and more particularly RNA virus infection from group IV or V. The term "controlling" is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate 5 a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment. The term “effective amount” includes “prophylaxis-effective amount” as well as “treatment-effective amount”. The term “preventing”, as used herein, means reducing the risk of onset or 10 slowing the occurrence of a given phenomenon, namely in the present invention, a disease resulting from a RNA virus infection, and more particularly a RNA virus infection from group IV or V. As used herein, « preventing » also encompasses « reducing the likelihood of occurrence » or « reducing the likelihood of reoccurrence ». 15              The term “prophylaxis-effective amount” refers to a concentration of compound of this invention that is effective in inhibiting, preventing, decreasing the likelihood of the disease by RNA viruses, and more particularly by a RNA virus from group IV or V of the Baltimore classification, or preventing the RNA virus infection and in particular a RNA virus infection from group IV or V or preventing the delayed onset of the disease by the RNA 20 virus, and more particularly by a RNA virus from group IV or V, when administered before infection, i.e. before, during and / or slightly after the exposure period to the RNA virus, and in particular to the RNA virus from group IV or V. Likewise, the term “treatment-effective amount” refers to a concentration of compound that is effective in treating the RNA virus infection, e.g. leads to a reduction in 25 RNA viral infection, following examination when administered after infection has occurred. As used herein, the term "pharmaceutically acceptable" refers to those compounds, materials, excipients, compositions or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problem complications commensurate 30 with a reasonable benefit / risk ratio. As used herein, a “viral infection or related condition” refers to an infection of condition related to a virus, more particularly said virus having a RNA genome, and 2019300101   30 Mar 2026 especially a RNA virus belonging to group IV or V according to the Baltimore classification. Viruses may be further classified in distinct families, orders and genus. For reference, the content of the “Baltimore classification” which is reported herein further references to the virus taxonomy as set forth in the database of the 2017 5 International Committee of Taxonomy of Viruses (ICTV) as released online on March 12, 2018 at http: / / ictvonline.org / virusTaxonomy.asp. This taxonomy is incorporated herein in its entirety. Alphaviruses may in particular be considered by the invention and pertain to the 10 Group IV RNA viruses and the Togaviridae family, which can be defined as positive-sense single-stranded RNA viruses or (+)ssRNA viruses. Their order is “Unassigned” according to the Virus Taxonomy of 2017. The Togaviridae family includes the Alphavirus and Rubivirus genus. Examples of Alphaviruses which are considered by the invention include: 15 Barmah Forest virus, Chikungunya virus, Mayaro virus, O’nyong’nyong virus, Ross River virus, Semliki Forest virus, Una virus, Eastern equine encephalitis virus, Tonate virus, Venezuelan equine encephalitis virus and Wester equine encephalitis virus. Most preferably, an alphavirus infection or alphavirus related condition, according to the invention, is a Chikungunya virus infection or Chikungunya virus-related 20 condition. More particularly, Chikungunya virus (CHIKV) is a RNA virus which pertains to the alphavirus genus which in turn belongs to the Togaviridae family, i.e. Group IV from the Baltimore classification. Chikungunya is a mosquito-borne viral disease first described during an outbreak in southern Tanzania in 1952. CHIKV is an enveloped, positive sense, 25 single-stranded RNA virus with a genome of approximately 12 kb nucleotides long. The genome of CHIKV is organized as follows: 5'-cap-nsPl-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6k-El-poly(A)-3', in which the first four proteins (nsPl-4) are nonstructural proteins, and the structural proteins are the capsid (C) and the envelope proteins (E). There is no distinct serotypic difference among CHIKV isolated from Africa, Asia and the islands 30 of the Indian Ocean. Phylogenetic analyses based on El gene sequences can group CHIKV into three genotypes (lineages): Asian, east / central / south African (ECSA), and West African. The Asian genotype differed from the ECSA and West African genotypes by 2019300101   30 Mar 2026 nucleotide levels of -5% and -15%, respectively. The African genotypes (ECSA versus West African) were -15% divergent. The amino acid identities across the three genotypes varied from 95.2 to 99.8%. Chikungunya virus may cause outbreaks associated with severe morbidity. 5              Chikungunya is a viral disease transmitted to humans by infected mosquitoes. Both Ae. aegypti and Ae. albopictus have been implicated in large outbreaks of Chikungunya. Whereas Ae. aegypti is confined within the tropics and sub-tropics, Ae. albopictus also occurs in temperate and even cold temperate regions. In recent decades, Ae. albopictus has spread from Asia to become established in areas of Africa, Europe and the 10 Americas. After infection with Chikungunya virus, there is an incubation period lasting 24 days on average, followed by disease symptoms. Among such symptoms, fever and severe joint pain may be cited. Other symptoms include muscle pain, headache, nausea, back pain, fatigue, myalgia and rash. Severe clinical manifestations of Chikungunya infection can also 15 occur, for example, haemorrhagic fever, conjunctivitis, photophobia, hepatitis, stomatitis. Neurologic manifestations such as encephalitis, febrile seizures, meningeal syndrome and acute encephalopathy were also reported. Joint pain is often debilitating and can vary in duration. The proximity of mosquito breeding sites to human habitation is a significant 20 risk factor for Chikungunya. The distribution of Chikungunya virus mainly occurs in Africa, India and South Eastern Asia. In recent decades, mosquito vectors of Chikungunya have spread to Europe and the Americas. In 2007, disease transmission was reported for the first time in a localized outbreak in north-eastern Italy. Outbreaks have since been recorded in France and Croatia. 25 Dengue viruses which present various serotypes, may also be considered by the invention and pertain to the Group IV RNA viruses and the Flaviviridae family, which can be defined as a positive-sense single-stranded RNA or (+)ss RNA viruses. More particularly Dengue virus, is a (+)ssRNA virus belonging to group IV of the Baltimore classification. It 30 is part of the Flavivirus genus, which belongs to the Flaviviridae family. Other viruses pertaining to the Flaviviridae family are hepatitis C virus and yellow fever virus. 2019300101   30 Mar 2026 Viruses of the Mononegavirales order are also particularly considered by the invention. The order Mononegavirales includes viruses belonging to Group V of the Baltimore classification. As of 2018, this order includes mainly the following virus families: Bornaviridae, Mymonaviridae, Filoviridae, Nyamiviridae, Paramyxoviridae, 5 Pneumoviridae, Rhabdoviridae, and Sunviridae. Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. HRSV virus may in particular be considered by the invention and pertain to the Group V of RNA viruses. More particularly, RSV virus 10 is a (-)ssRNA virus belonging to group V of the Baltimore classification. It is a pneumovirus which is part of the Paramyxoviridae family, which belongs to the Mononegavirales order. Among other viruses of the Mononegavirales order, those which are particularly considered by the invention include: measles virus, mumps virus, Nipah virus, rabies virus, and human parainfluenza virus (which includes HPIV-1, HPIV-2, HPIV-3 and HPIV-4). Of note, the 15 Paramyxovirinae subfamily was conventionally merged into the Paramyxoviridae family, by reference to the taxonomy of the Mononegavirales order updated in 2016. The virus genus which are particularly considered within the Paramyxoviridae family include: Aquaparamyxovirus, Avulavirus, Ferlavirus, Henipavirus, Morbillivirus, Respirovirus and Rubulavirus genus. 20 Viruses of the Orthomyxoviridae family are also particularly considered by the invention. The Orthomyxoviridae family belongs to an “Unassigned” order according to the 2017 Virus Taxonomy. The virus genus which are particularly considered within the Orthomyxoviridae family include: Alphainfluenzavirus, Betainfluenzavirus, 25 Deltainfluenzavirus, Gammainfluenzavirus, Isavirus, Quaranjavirus, and Thogotovirus. Influenzavirus A, Influenzavirus B, Influenzavirus C may in particular be considered by the invention and pertain to the Group V RNA viruses and the Orthomyxoviridae family, which can be defined as a negative-sense single-stranded RNA or (-)ss RNA viruses. Isavirus and Thogotovirus also belong to the Orthomyxoviridae order. 30              The term “comprising” as used in this specification and claims means “consisting at least in part of”. When interpreting statements in this specification and claims which include the term “comprising”, other features besides the features prefaced by this 2019300101   30 Mar 2026 term in each statement can also be present. Related terms such as “comprise” and “comprises” are to be interpreted in similar manner. SUMMARY OF THE INVENTION 5               In a first aspect, the present invention provides a method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral 10 infection, comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound of formula (I): (I) wherein: ring independently mean a phenylene or a pyridylene group, 15 X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group, 20 X2 represents a -O- group, a-CO-NH- group, a -NH-CO-NH- group, 25     a -OCH2- group, a -NH-CO- group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms 2019300101   30 Mar 2026 or a -SO2-NH- group, n is 0, 1, 2 or 3, 5 m and m’ are independently 0, 1 or 2, Y2 represents a hydrogen atom, 10 a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or 15 a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally substituted by one or two (C1-C4)alkyl group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl 20 group being optionally interrupted on said R1 and / or R2 by an oxygen atom, or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl 25 derivative, or by a trifluoromethyl group, R and R’ independently represent a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, 30 a halogen atom, a (C1-C5)alkoxy group, a -SO2-NRaRb group, 2019300101   30 Mar 2026 a -SO3H group, a -OH group, or a -O-SO2-ORc group, Ra, Rb, Rc and Rd independently represent a hydrogen atom or a (C1-C4)alkyl group, 5 provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group optionally substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or 10   a -O-P(=O)-(ORc)(ORd) group, or any of its pharmaceutically acceptable salt.In a second aspect, the present invention provides a method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the 15 Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection, comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound of formula (Ia) (-La) 20 wherein Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined in the first aspect, or any of its pharmaceutically acceptable salt. In a third aspect, the present invention provides a method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or 25 V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral 2019300101   30 Mar 2026 infection, comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound of formula (Ib) (Ib) wherein Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined in the first aspect, or any of its pharmaceutically acceptable salt. In a fourth aspect, the present invention provides a method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or 10 V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection, comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound of formula (Id) (Id) wherein 15 Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined in the first aspect, or any of its pharmaceutically acceptable salt. 20 In a fifth aspect, the present invention provides a method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral 2019300101   30 Mar 2026 infection, comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound selected from 1 ^^^H^H^ O             1 2 A A. n           / ,- n / / / hi r h h n'A / ' H 3 QA n    AJ A r n H A yA AA . n. z\ / N H                II O              1 4 / -. N              All H A / A As JA / N. Z\ / . N   X  X > H                II o    AA 5 ^Ac^xx^ H O 6 NYA Al H A„A / AJA / n. z\ n   AA   Y\ H              II                      / o 7 Cv^ / -. n      t A r ii H A,A / AJA / Nx / \ / n^ H H        O O        1 8 0_ / . n h AA / AJA / n. / \ n   X H          II           V O 9 1 '                  H            H O 10 Ca^. / . NAn JJ h AA A JA / n. / \ ^ / \ N N         T^\ H              II                      / O       1— / 2019300101   30 Mar 2026 103 IZ O ZI A) \=z 104 [IJ N\A\A\x'X1 XW H                  ||               ' O 105 o NxAAvA 1 1 \ Il H <   AA zN\ / \ / \ n^    A-A     X H                  II O     \^A 106 X- N       A h   CO < A / A A. / n.     / N^ J N H        A A O O 107 / . n       if A n^ 7i             r o H                           1 I IL A\ AA / N\    ,n. J n        >r H                  II O 108 ^A^H^N^o O 109 CA-^ n >< A n^ n           r n 1                           H                          1             | \ xA A A / N. X\ / N. J N    Y H                  II O 110 zO 4 \A IZ A ZI o \ 1—‘ oo 1—‘ 1—‘ 1—‘ 1—‘ (lb) 114 113 112 in ■p IZ J ZI p IZ ZI ■p IZ 2' ZI p IZ ZI ■l=I = ',= 0             1 H           1   7--\    / __ / N— IZ ZI o \ 0 Xj 4 / IZ ZI Q 2019300101   30 Mar 2026 115 d X N id jd .''^''''^^O'''''''''-'^^ H 116 -’H'^? / \   0^^.^^^ 117 d^ N 0 'dv? A 0 Nh F F F 118 dd o N   nN 0 119 dd O 'd^G^jO 0 120 dd o 0 121 dd o N   H         .      . H            1    7   \ N^n    oh (Id) 2019300101   30 Mar 2026 or any of its pharmaceutically acceptable salt. In a sixth aspect, the present invention provides a compound or any of its pharmaceutically acceptable salt, which is selected from (1) a compound of formula (Ia) as defined in the second aspect Wherein 2 (Ia) n, X2, Y2, R, R’, m and m’ are as defined in the first aspect, Y1 is a 2-pyridyl group, 3-pyridyl or a pyrazinyl group, 2019300101   30 Mar 2026 the group group, - X^CH^Y2 is in meta position on the ring, with respect to the -NH- the ring is a phenylene group, and (2) a compound of formula (Ib) as defined in the third aspect O R'm' Rm X^CH-^Y2 2 n (Ib) 10 wherein n, X2, Y2, R, R’, m, m’ and Z ring are as defined in the first aspect, Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen of the pyrimidinyl group being in the ortho position with respect to the -NH-CO-group, with the proviso that the following compound is excluded: 15 (3) a compound of formula (Id) as defined in the fourth aspect 2019300101   30 Mar 2026 wherein n, X2, Y2, R, R’, m, m’ and Z ring are as defined in the first aspect, Y1 is a 2-pyridyl group, with the proviso that the following compound is excluded: In a seventh aspect, the present invention provides a compound of formula (Ia), (Ib) and (Id) as defined in the sixth aspect or any of its pharmaceutically acceptable salts, or any of compounds (3) to (18), (32) to (35), (91) to (122) as defined in the fifth or any of its 10 pharmaceutically acceptable salts, for use as a medicament. In an eighth aspect, the present invention provides a pharmaceutical composition comprising at least one compound as defined in the sixth aspect or any one of its pharmaceutically acceptable salts, or at least any of compounds (3) to (18), (32) to (35), (91) 15 to (122) as defined in the fifth aspect or any of its pharmaceutically acceptable salts and also at least one pharmaceutically acceptable excipient. In a ninth aspect, the present invention provides a synthesis process for manufacturing compounds of formula (Ia), (Ib), and (Id) as defined in the sixth aspect, 20 comprising at least a step of coupling a compound of formula (II) Rm' NH2 (II) with a compound of formula (III) Rm (III) 2019300101   30 Mar 2026 wherein X1, Y1, R, R’, m, m’, n, ring, ring, X2, Y2 are as defined in the sixth aspect and X is a chlorine atom, an iodine atom or a bromine atom, in presence of an inorganic base and a diphosphine and in the presence of an organometallic catalyst, to obtain a compound of formula (Ia), (Ib) or (Id) as defined in the sixth aspect. 5               In a tenth aspect, the present invention relates to use, in the manufacture of a medicament for the treatment or prevention of a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and 10 a Dengue viral infection, of a compound of formula (I): (I) wherein: ring independently mean a phenylene or a pyridylene group, 15 X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group, 20   X2 represents a -O- group, a-CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, 25 a -NH-CO- group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms 2019300101   30 Mar 2026 or a -SO2-NH- group, n is 0, 1, 2 or 3, 5 m and m’ are independently 0, 1 or 2, Y2 represents a hydrogen atom, 10 a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or 15 a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally substituted by one or two (C1-C4)alkyl group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl 20 group being optionally interrupted on said R1 and / or R2 by an oxygen atom, or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl 25 derivative, or by a trifluoromethyl group, R and R’ independently represent a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, 30 a halogen atom, a (C1-C5)alkoxy group, a -SO2-NRaRb group, 2019300101   30 Mar 2026 10 a -SO3H group, a -OH group, or a -O-SO2-ORc group, Ra, Rb, Rc and Rd independently represent a hydrogen atom or a (C1-C4)alkyl group, provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group optionally substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group, or any of its pharmaceutically acceptable salt. In an eleventh aspect, the present invention relates to use of a compound of 15 formula (Ib) (Ib) wherein Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined in the first aspect, 20 or any of its pharmaceutically acceptable salt, in the manufacture of a medicament for the treatment or prevention of a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection. 25 1. Use of a compound of formula (Id) (Id) wherein 2019300101   30 Mar 2026 Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined in the first aspect, or any of its pharmaceutically acceptable salt, in the manufacture of a medicament for the treatment or prevention of a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, 5 wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection. In a twelfth aspect, the present invention relates to use, in the manufacture of a medicament for the treatment or prevention of a RNA virus infection caused by a virus 10 belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection, of a compound selected from to 99 98 97 96 95 94 93 A n=n \___ /   1          H T J X 1 zy^ yx IZ X ■ Cx* yx IZ . - zyz X yx IZ J ZI J 1 ,1,. 0              1 Z^ yx IZ x X Ay     o o /               \\ / /          H \ nx X Ay vx y H U LA AxXxAA\n Ph 9Z 2019300101   30 Mar 2026 100 N H           I / ---\ N=N y- 101 IZ -- ZI 102 N 1      ■ N - -   , H         / / X / O O          1 103 N1 A- V - O       1— / 104 Z---V 4 4 / IZ - ZI / 105 z--< 47 47 IZ - ZI J 106 H         / / x / O O 2019300101   30 Mar 2026 107 N           X N n              1 O 1                           H                           1             1 k / X A / k / N\    / N\ N    y H                  II O 108 zO 4 4 / IZ •> ZI o 109 Cx^,       / - / N X X N^ >         r n 1                           H                          1             1 k zk / A A / N.     / N. J N H                  || O 110 N                     H N        H          "' N O 111 o IZ - ZI 4 \ z 112 a IZ ZI 4 \ z 113 N N O 114 ^ / O. Xl X^Xn'-X^ H           ' / \    / N^N __NN— (Ib) 117 116 115 1—‘ oo 1—‘ 1—‘ 1—‘ 1—‘ 7 V" V 97 i, । A 9 IZ / =° 9-9 / IZ o 9 IZ 7 ZI p IZ 7 ZI 9 IZ 7 7 ZZE p ZEZ - 7 ZI A p IZ ZT - UJ o 2019300101   30 Mar 2026 or any of its pharmaceutically acceptable salt. In a thirteenth aspect, the present invention relates to use of a compound of formula (Ia), (Ib) and (Id) as defined in the sixth aspect or any of its pharmaceutically 5 acceptable salts, and any of compounds (3) to (18), (32) to (35), (91) to (122) as defined in the fifth aspect or any of its pharmaceutically acceptable salts, in the manufacture of a medicament. In the description in this specification reference may be made to subject matter which is not within the scope of the appended claims. That subject matter should be readily 10 identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the appended claims. In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated 15 otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art. DETAILED DESCRIPTION OF THE INVENTION 20              The inventors have surprisingly found that aryl-N-aryl compounds are endowed with a broad-spectrum activity against RNA viruses, and more particularly single-stranded RNA viruses belonging to Group IV or V of the Baltimore classification. Groups IV and V include respectively (+)ssRNA viruses and (-)ssRNA viruses; which also refer to positivesense single-stranded RNA viruses and negative-sense single-stranded RNA viruses. 25               For reference, the content of the « Baltimore classification » is considered in light of the Classification and Nomenclature of viruses as set forth in the 10th report on Virus Taxonomy dated 2017. 2019300101   30 Mar 2026 The present document discloses a compound of formula (I) (I) wherein: group, ring independently mean a phenylene or a pyridylene wherein the group is in meta or para position on the 10 ring, in particular in meta position, with respect to the -NH- group, X1 represents an alkenylene group, in particular an ethenylene group, a -NH-CO- group, a -CO-NH- group, a -CRaRbO- group, Y1 represents an aryl group selected from a 2-pyridyl group or a pyrimidinyl group, wherein one of the nitrogen atom of the pyrimidinyl group is in ortho position with respect to X1, or alternatively X1-Y1 represents a group (A) of formula 15 20 X2 represents a -CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, a -NH-CO- group or a -SO2-NH- group, n is 0, 1, 2 or 3, m and m’ are independently 0, 1 or 2, Y2 represents a hydrogen atom, a hydroxyl group or a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally 2019300101   30 Mar 2026 substituted by one or two (C1-C4)alkyl group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, R and R’ independently represent a halogen atom, a (C1-C4)alkyl group, a 5               (C3-C6)cycloalkyl group, a (C1-C5)alkoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group, Ra, Rb, Rc and Rd independently represent a hydrogen atom or a (C1-C4)alkyl group, provided that when X1 is a -CRaRbO- group, Y1 may further be a 3-pyridyl, a 10              4-pyridyl or a phenyl group optionally substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group, 15               or any of its pharmaceutically acceptable salt, for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification and in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 20 According to a first aspect, the present invention relates to a compound of formula (I) 25 wherein (I) group, ring independently mean a phenylene or a pyridylene 2019300101   30 Mar 2026 X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a 5 pyrimidinyl group, X2 represents a -O- group, a-CO-NH- group, a -NH-CO-NH- group, 10 a -OCH2- group, a -NH-CO- group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, such as a triazole or an oxadiazole, or 15 a -SO2-NH- group, n is 0, 1, 2 or 3, m and m’ are independently 0, 1 or 2, 20 Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, 25 a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that 30 no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally substituted by one or two (C1-C4)alkyl 2019300101   30 Mar 2026 group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd 5 form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or by a trifluoromethyl group, R and R’ independently represent 10                  a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a -SO2-NRaRb group, 15                a -SO3H group, a -OH group, or a -O-SO2-ORc group, provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group 20              optionally substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group, or any of its pharmaceutically acceptable salt, 25              for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. According to a second aspect, the present invention relates to compounds of formula (I) as defined above for use in the treatment and / or prevention of a RNA virus 30 infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition, and even more particularly a 2019300101   30 Mar 2026 RSV viral infection, a Chikungunya viral infection and a Dengue viral infection or a virus-related condition. According to a third aspect, the present invention relates a compound of 5 formula (Ia), wherein 2 (Ia) Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined above, or any of its pharmaceutically acceptable salt, 10              for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 15               Still according to this third aspect, the present invention relates to the compound of formula (Ia) for use as defined above, wherein ring is a phenylene group or a pyridylene group, Y1 represents a 2-pyridyl group, a 3-pyridyl group or a pyrazinyl group, n is 1, 2 or 3, m is 0, 20              R’ is a halogen atom, a (C1-C2)alkoxy group or a (C1-C2)alkyl group, X2 represents a -CO-NH- group, a -SO2NH- group or a divalent triazole group, Y2 represents a morpholinyl group, a piperidinyl group or a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, 25                 a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than 2019300101   30 Mar 2026 one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally 5                 substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt. Still according to said third aspect, the present invention further relates to 10 compounds of formula (Ia) as defined above, wherein ring is a phenylene group or a pyridylene group, Y1 represents a 2-pyridyl group, n is 2, m is 0, R’ is a halogen atom, a (C1-C2)alkoxy group or a (C1-C2)alkyl group, 15              Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, or any of its pharmaceutically acceptable salt, 20              for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 25              According to a fourth aspect, the present invention relates to a compound of formula (Ib), (Ib) 2019300101   30 Mar 2026 wherein Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined above, or any of its pharmaceutically acceptable salt, for use in the treatment and / or prevention of a RNA virus infection caused by a 5 RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. Still according to this fourth aspect, the present invention relates to the compound 10 of formula (Ib) for use as defined above, wherein 0 ring is a phenylene group, Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen atom of the pyrimidinyl group being in the ortho position with respect to the -NH-CO-group, 15 n is 1, 2 or 3, m is 0, m’ is 0 or 1, R’ is a (C3-C6)cycloalkyl group, X2 represents a -CO-NH- group, a -O- group or a divalent triazole, Y2 represents a hydroxyl group, 20 a morpholinyl group, a piperidinyl group or a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the 25 carbon atom bearing them a (C3-C6)cycloalkyl group, said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, or any of its pharmaceutically acceptable salt. 2019300101   30 Mar 2026 Still according to said fourth aspect, the present invention further relates to compounds of formula (Ib) as defined above, wherein ring is a phenylene group, Y1 is a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen atom of 5              the pyrimidinyl group being in the ortho position with respect to the -NH-CO- group, n is 1 or 2, m and m’ are 0, X2 represents a -CO-NH- group, Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent 10              a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, or any of its pharmaceutically acceptable salt, 15              for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 20              According to a fifth aspect, the present invention relates to a compound of formula (Id), wherein (Id) Y1, R, R’, m, m’, ring, X2, n and Y2 are as defined above, 25 or any of its pharmaceutically acceptable salt, 2019300101   30 Mar 2026 for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 5 Still according to this fifth aspect, the present invention relates to the compound of formula (Id) for use as defined above, wherein [0 ring is a phenylene group, Y1 represents a 2-pyridyl group or a 3-pyridyl group, 10              X2 represents a -CO-NH- group, a -SO2-NH- group or a divalent triazole, m’ and m are 0, n is 1, 2 or 3, Y2 represents a hydroxyl or a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and 15              R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, or any of its pharmaceutically acceptable salt. Still according to said fifth aspect, the present invention further relates to 20 compounds of formula (Id), wherein ring is a phenylene group, the group ' the -NH- group, ■2 is in meta position on the ring with respect to Y1 represents a 2-pyridyl group, m’ and m are 0, n is 2, 25              Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, 2019300101   30 Mar 2026 or any of its pharmaceutically acceptable salt, for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV 5 viral infection or a virus-related condition. The above-mentioned compounds (I), (Ia), (Ib) and (Id) are particularly suitable for treating or preventing a virus infection or related condition, in particular a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification 10 or related condition, and most preferably a Chikungunya viral infection, a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. The above-mentioned compounds are even more particularly suitable for treating or preventing a Chikungunya viral infection, a Dengue viral infection or a RSV viral infection or a virus-related condition, most particularly a RSV viral infection. 15               Further aspects of the present invention will be described herein after such as the use of new compounds of formula (I), (Ia), (Ib) and (Id) as a medicament, a pharmaceutical composition and a synthetic process. According to a particular embodiment, a subject-matter of the present document 20 describes a compound of formula (I) as defined above, wherein the alkenylene group is a (E)-alkenylene group, m and m’ are independently 0 or 1, Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C2)alkyl group, being understood that 25              no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, said (C3-C6)cycloalkyl group being optionally substituted by one or two halogen atoms and said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, 30              R and R’ independently represent a halogen atom, a (C1-C2)alkyl group, a (C3-C6)cycloalkyl group, or a (C1-C2)alkoxy group, or any of its pharmaceutically acceptable salt, 2019300101   30 Mar 2026 for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 5 According to a further embodiment, the present document describes a compound of formula (I) 10 wherein: (I) group, ring independently mean a phenylene or a pyridylene wherein the group is in meta or para position on the ring, with respect to the -NH- group, 15 X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, 20 a -CRaRbO- group, Y1 represents an aryl group selected from a 2-pyridyl group or a pyrimidinyl group, wherein one of the nitrogen atom of the pyrimidinyl group is in ortho position with respect to X1, or alternatively X1-Y1 represents a group (A) of formula X2 represents a -CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, a -NH-CO- group or a -SO2-NH- group, 2019300101   30 Mar 2026 n is 0, 1, 2 or 3, m and m’ are independently 0, 1 or 2, Y2 represents a hydrogen atom, a hydroxyl group or a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a 5 (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally substituted by one or two (C1-C4)alkyl group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl group being optionally interrupted on said R1 10 and / or R2 by an oxygen atom, R and R’ independently represent a halogen atom, a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)alkoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group, Ra, Rb, Rc and Rd independently represent a hydrogen atom or a (C1-C4)alkyl 15 group, provided that when X1 is a -CRaRbO- group, Y1 may further be a 3-pyridyl, a 4-pyridyl or a phenyl group optionally substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group, 20 a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group, and provided that when Y1-X1 represents a 2-pyridylethenylene group, X2 represents a -CO-NH- group and Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C4)alkyl group, and 25 m’ is different from 0, or any of its pharmaceutically acceptable salt, for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. 30 Still according to a particular embodiment, the present invention is directed to new compounds, encompassed within formula (I). 2019300101   30 Mar 2026 Said new compounds, which may also be under the form of acceptable salts, are selected from (1) a compound of formula (Ia) as defined above for formula (I) wherein Y1 is a 2-pyridyl group, 3-pyridyl or a pyrazinyl group, the group ' the -NH- group, is in meta position on the ring, with respect to X2, Y2, n, R, R’, m and m’ are as defined above, the ring is a phenylene group, and 10 15 with the proviso that compounds 1 and 2 as defined herein after are excluded, (2) a compound of formula (Ib) as defined above for formula (I) wherein Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen of the pyrimidinyl group being in the ortho position with respect to X1, X2, Y2, n, R, R’, ring, m and m’ are as defined above, and (4) a compound of formula (Id) as defined above for formula (I) wherein 20              Y1 is a 2-pyridyl group or a 3-pyridyl group, and R, R’, m, m’, ring, X2, n and Y2 are as defined above. According to another aspect, a subject-matter of the present invention relates to a new compound of formula (Ia), (Ib), and (Id) as defined just above or any of its 25 pharmaceutically acceptable salts, and any of compounds (3) to (18), (32) to (35), (91) to 2019300101   30 Mar 2026 (122) as defined herein after or any of its pharmaceutically acceptable salts, for use as a medicament. Any combination of the above-defined embodiments for R, R’, m, m’, ring, ring, X1, X2, n, Y1, Y2 with each other does form part of the instant invention. According to a particular embodiment, the present invention relates to a compound of formula (I) for use as defined above, wherein ring both represent a phenylene group. 10              According to a particular embodiment, a subject-matter of the present document describes a compound of formula (Ia) as defined above, wherein the alkenylene group is a (E)-alkenylene group, m and m’ are independently 0 or 1, 15              Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, said (C3-C6)cycloalkyl group being optionally substituted by one or two halogen 20              atoms and said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, R and R’ independently represent a halogen atom, a (C1-C2)alkyl group, a (C3-C6)cycloalkyl group, or a (C1-C2)alkoxy group, or any of its pharmaceutically acceptable salt, 25              for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 2019300101   30 Mar 2026 According to a particular embodiment, a subject-matter of the present document describes a compound of formula (Ib) as defined above, wherein 5              m and m’ are independently 0 or 1, Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, said 10              (C3-C6)cycloalkyl group being optionally substituted by one or two halogen atoms and said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, R and R’ independently represent a halogen atom, a (C1-C2)alkyl group, a (C3-C6)cycloalkyl group, or a (C1-C2)alkoxy group, 15               or any of its pharmaceutically acceptable salt, for use in the treatment and / or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. 20 According to a particular embodiment, a subject-matter of the present document describes a compound of formula (Id) as defined above, wherein m and m’ are independently 0 or 1, 25              Y2 represents a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, said (C3-C6)cycloalkyl group being optionally substituted by one or two halogen 30              atoms and said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom, 2019300101   30 Mar 2026 R and R’ independently represent a halogen atom, a (C1-C2)alkyl group, a (C3-C6)cycloalkyl group, or a (C1-C2)alkoxy group, or any of its pharmaceutically acceptable salt, for use in the treatment and / or prevention of a RNA virus infection caused by a 5 RNA virus belonging to group IV or V of the Baltimore classification, and in particular a Chikungunya viral infection a Dengue viral infection, an Influenza viral infection or a RSV viral infection or a virus-related condition. In another embodiment, the present invention relates to the compounds of 10 formula (I) for use as defined above, wherein Y1 represents a 2-pyridinyl group or a 3-pyridinyl group, a pyrimidinyl group or a pyrazinyl group, with one of the nitrogen atoms 15   being in ortho position with respect to X1, provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group, or any of its pharmaceutically acceptable salt. In another embodiment, in the compounds of formula (I), for use as defined 20 above, wherein X2 represents a -O- group, a-CO-NH- group, a divalent triazole, 25                 or a -SO2-NH- group, or any of its pharmaceutically acceptable salt. In another embodiment, the present invention relates to the compound of formula 30   (I), for use as defined above, wherein Y2 represents a hydroxyl group, 2019300101   30 Mar 2026 a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or 5                a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, or any of its pharmaceutically acceptable salt. 10 In another embodiment, the present invention relates to the compound of formula (I), for use as defined above, wherein R and R’ independently represent a (C1-C4)alkyl group, 15                  a (C3-C6)cycloalkyl group, a halogen atom, or a (C1-C5)alkoxy group, or any of its pharmaceutically acceptable salt. Any combination of the above-defined embodiments for R, R’, m, m’, 20 ring, ring, X1, X2, n, Y1, Y2 with each other does form part of the instant invention. In another embodiment, the present invention relates to the compound of formula (I), for use as defined above, wherein ring both represent a phenylene group, 25 R” is a hydrogen atom, Y1 represents a 2-pyridinyl group provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group, X2 represents a -O- group, a-CO-NH- group, 2019300101   30 Mar 2026 Y2 represents a -CR1R2R3 group, wherein R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group and R3 represents a hydrogen atom or a (C1-C4)alkyl group, and R and R’ represents a hydrogen atom or a (C3-C6)cycloalkyl group, such as a 5              cyclopropyl group, or any of its pharmaceutically acceptable salt. According to a preferred embodiment of the present invention, the compound of formula (I) is chosen from: 10              - (1) (E)-N-isopentyl-3-((4-(2-(pyridin-2-yl)vinyl)phenyl)amino)benzamide - (2) (E)-N-isopentyl-4-((4-(2-(pyridin-2-yl)vinyl)phenyl)amino)benzamide -              (3)              (E)-N-isopentyl-3-((3-methoxy-4-(2-(pyridin-2- yl)vinyl)phenyl)amino)benzamide -              (4)              (E)-N-(2-cyclohexylethyl)-3-((4-(2-(pyridin-2- 15 yl)vinyl)phenyl)amino)benzamide - (5) (E)-N-neopentyl-3-((4-(2-(pyridin-2-yl)vinyl)phenyl)amino)benzamide -              (6)              (E)-N-(2-cyclopentylethyl)-3-((4-(2-(pyridin-2- yl)vinyl)phenyl)amino)benzamide -                   (7)                   (E)-N-isopentyl-3-((4-(2-(pyridin-2- 20 yl)vinyl)phenyl)amino)benzenesulfonamide -              (8)              (E)-N-(2-cyclopropylethyl)-3-((4-(2-(pyridin-2- yl)vinyl)phenyl)amino)benzamide -              (9)              (E)-N-(2-cyclobutylethyl)-3-((4-(2-(pyridin-2- yl)vinyl)phenyl)amino)benzamide 25               -             (10)             (E)-N-(2-cyclopentylethyl)-6-((4-(2-(pyridin-2- yl)vinyl)phenyl)amino)picolinamide -         (11) (E)-N-(2-cyclohexylethyl)-3-((3-fluoro-4-(2-(pyridin-2- yl)vinyl)phenyl)amino)benzamide -        (12) (E)-N-(2-cyclopentylethyl)-3-((2-methyl-4-(2-(pyridin-2- 30 yl)vinyl)phenyl)amino)benzamide -              (13)              (E)-N-isopentyl-3-((2-methyl-4-(2-(pyridin-2- yl)vinyl)phenyl)amino)benzamide 2019300101   30 Mar 2026 - (14) N-isopentyl-3-((4-(pyridin-2-ylcarbamoyl)phenyl)amino)benzamide -                 (15)                 N-(2-cyclopentylethyl)-3-((4-(pyridin-2- ylcarbamoyl)phenyl)amino)benzamide -                 (16)                 N-(2-cyclohexylethyl)-3-((4-(pyridin-2- 5 ylcarbamoyl)phenyl)amino)benzamide -               (17)               N-(2-cyclopentylethyl)-3-((4-(pyrimidin-4- ylcarbamoyl)phenyl)amino)benzamide - (18) N-isopentyl-3-((4-(pyrimidin-2-ylcarbamoyl)phenyl)amino)benzamide - (32) N-(4-((3-(isopentylcarbamoyl)phenyl)amino)phenyl)picolinamide 10              - (33) N-(4-((3-(neopentylcarbamoyl)phenyl)amino)phenyl)picolinamide - (34) N-(4-((3-(N-isopentylsulfamoyl)phenyl)amino)phenyl)picolinamide -                                (35)                                N-(4-((3-((2- cyclopentylethyl)carbamoyl)phenyl)amino)phenyl)picolinamide - (91)   3-({3-methoxy-4-[(E)-2-(pyridin-3-yl)ethenyl]phenyl}amino)-N-[3- 15 (morpholin-4-yl)propyl]benzamide -    (92) 3-({2-methyl-4-[(E)-2-(pyridin-3-yl)ethenyl]phenyl}amino)-N-[3- (morpholin-4-yl)propyl]benzamide -             (93)             N-(2-cyclopentylethyl)-3-({4-[(E)-2-(pyridin-3- yl)ethenyl]phenyl}amino)benzene-1-sulfonamide 20               - (94) 4-[(E)-2-(pyridin-2-yl)ethenyl]-N-{3-[4-(trifluoromethyl)piperidine-1- carbonyl]phenyl}aniline -               (95)               N-(3-methylbutyl)-3-({4-[(E)-2-(pyrazin-2- yl)ethenyl]phenyl}amino)benzamide -             (96)             N-(2-cyclopentylethyl)-3-({4-[(E)-2-(pyrazin-2- 25 yl)ethenyl]phenyl}amino)benzamide - (97) N-[3-(4,4-dimethylpiperidine-1-carbonyl)phenyl]-4-[(E)-2-(pyridin-2-yl)ethenyl]aniline - (98) N-(3-{8-azaspiro[4.5]decane-8-carbonyl}phenyl)-4-[(E)-2-(pyridin-2-yl)ethenyl]aniline 30               - (99) 3-[4-(2-methylpropyl)-1H-1,2,3-triazol-1-yl]-N-{4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}aniline 2019300101   30 Mar 2026 - (100) 3-[4-(2-methylpropyl)-1H-1,2,3-triazol-1-yl]-N-{4-[(E)-2-(pyridin-3-yl)ethenyl]phenyl}aniline -               (101)               N-(3-methylbutyl)-3-({4-[(E)-2-(pyridin-3- yl)ethenyl]phenyl}amino)benzamide 5               -               (102)               N-(3-methylbutyl)-3-({4-[(E)-2-(pyridin-3- yl)ethenyl]phenyl}amino)benzene-1-sulfonamide -            (103)            N-(2-cyclopentylethyl)-3-({4-[(E)-2-(pyridin-3- yl)ethenyl]phenyl}amino)benzamide -           (104)           N-(2,2-dimethylpropyl)-3-({4-[(E)-2-(pyridin-3- 10 yl)ethenyl]phenyl}amino)benzamide -             (105)             N-(2-cyclohexylethyl)-3-({4-[(E)-2-(pyridin-3- yl)ethenyl]phenyl}amino)benzamide -         (106)        N-[3-(morpholin-4-yl)propyl]-3-({4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}amino)benzene-1-sulfonamide 15               -         (107)        N-[3-(morpholin-4-yl)propyl]-2-({4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}amino)pyridine-4-carboxamide -         (108)        N-[3-(morpholin-4-yl)propyl]-6-({4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}amino)pyridine-2-carboxamide -     (109)     N-[3-(4-methylpiperazin-1-yl)propyl]-2-({4-[(E)-2-(pyridin-2- 20 yl)ethenyl]phenyl}amino)pyridine-4-carboxamide -     (110)     N-[3-(4-methylpiperazin-1-yl)propyl]-6-({4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}amino)pyridine-2-carboxamide -         (111)        N-[3-(morpholin-4-yl)propyl]-3-({4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}amino)benzamide 25               -          (112)          N-[3-(piperidin-1-yl)propyl]-3-({4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}amino)benzamide -     (113) N-[3-(4-methylpiperazin-1-yl)propyl]-3-({4-[(E)-2-(pyridin-2- yl)ethenyl]phenyl}amino)benzamide -   (114)   3-{4-[(diethylamino)methyl]-1H-1,2,3-triazol-1-yl}-N-{4-[(E)-2- 30 (pyridin-2-yl)ethenyl]phenyl}aniline -     (115)    4-{[3-(3-cyclohexylpropoxy)phenyl]amino}-3-cyclopropyl-N- phenylbenzamide 2019300101   30 Mar 2026 - (116)   3-cyclopropyl-4-({2-[(3-methylbutyl)carbamoyl]phenyl}amino)-N- (pyrimidin-2-yl)benzamide -            (117)            3-cyclopropyl-N-(pyrimidin-2-yl)-4-({2-[(3,3,3- trifluoropropyl)carbamoyl]phenyl}amino)benzamide 5              -    (118) 4-[(3-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)amino]-N- (pyridin-2-yl)benzamide - (119) 4-[(3-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)amino]-N-(pyridin-2-yl)benzamide - (120) 4-[(3-{[3-(4-methylpiperazin-1-yl)propyl]carbamoyl}phenyl)amino]-N-10 (pyridin-2-yl)benzamide - (121) 4-({3-[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]phenyl}amino)-N-(pyridin-2-yl)benzamide -           (122)           N-[4-({3-[4-(2-methylpropyl)-1H-1,2,3-triazol-1- yl]phenyl}amino)phenyl]pyridine-2-carboxamide 15               and their pharmaceutically acceptable salts. The present invention extends to compounds (3) to (18), (32) to (35), (91) to (122) and their pharmaceutically acceptable salts, such as hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tosylate, triflate, maleate, mesylate, formate, 20 acetate and fumarate. According to another aspect, a subject-matter of the present invention relates to a compound of formula (I), (Ia), (Ib) and (Id) as defined above or any of its pharmaceutically acceptable salts, and any of compounds (1) to (18), (32) to (35) and (91) to (122) or any of 25 its pharmaceutically acceptable salts, for use as an agent for preventing, inhibiting or treating a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. Compounds of formula (I) as defined above for which 0 © 30                      ring and ring both represent a phenylene group, 2019300101   30 Mar 2026 Y1 represents a 2-pyridinyl group provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group, X2 represents a -O- group, a-CO-NH- group, Y2 represents 5                a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group and R3 represents a hydrogen atom or a (C1-C4)alkyl group, or 10                a morpholinyl group, and R and R’ independently represent a hydrogen atom, (C1-C4)alkyl group, such as a methyl group, or a (C3-C6)cycloalkyl group, such as a cyclopropyl group, or any of its pharmaceutically acceptable salt, may be particularly suitable for use as an agent for preventing, inhibiting or treating a RNA virus infection caused by a RNA 15 virus belonging to group IV or V of the Baltimore classification. Compounds (12), (13), (15) and (35) or any of their pharmaceutically acceptable salts may be particularly useful for preventing, inhibiting or treating dengue infection. Compounds (12), (13), (16) and (115) or any of their pharmaceutically acceptable 20 salts may be particularly useful for preventing, inhibiting or treating RSV infection. Compounds (1), (2), (4), (6), (9), (12), (13), (14), (15), (16), (32), (35) or any of their pharmaceutically acceptable salts may be particularly useful for preventing, inhibiting or treating Chikungunya infection. 25              The compounds of the invention may exist in the form of free bases or of addition salts with pharmaceutically acceptable acids. « Pharmaceutically acceptable salt thereof » refers to salts which are formed from acid addition salts formed with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), as well as salts formed with 30 organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, 2019300101   30 Mar 2026 polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and poly-galacturonic acid. Suitable physiologically acceptable acid addition salts of compounds of formula (I) include hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tosylate, 5 triflate, maleate, mesylate, formate, acetate and fumarate. The compounds of formula (I), (Ia), (Ib) and (Id) and any of compounds (1) to (18), (32) to (35) and (91) to (122) or any of their pharmaceutically acceptable salts may form solvates or hydrates and the invention includes all such solvates and hydrates. The terms "hydrates" and "solvates" simply mean that the compounds (I), (Ia), 10 (Ib) and (Id) according to the invention can be in the form of a hydrate or solvate, i.e. combined or associated with one or more water or solvent molecules. This is only a chemical characteristic of such compounds, which can be applied for all organic compounds of this type. In the context of the present invention, the term: 15              - “halogen” is understood to mean chlorine, fluorine, bromine, or iodine, and in particular denotes chlorine, fluorine or bromine, - “(C1-Cx)alkyl”, as used herein, respectively refers to a C1-Cx normal, secondary or tertiary saturated hydrocarbon, for example (C1-C6)alkyl. Examples are, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, butyl, pentyl, 20              - an “alkenylene” means a divalent (C1-Cx)alkyl group comprising a double bond, and more particularly an ethenylene group, also known as vinylene or 1,2-ethenediyl, - “(C3-C6)cycloalkyl”, as used herein, refers to a cyclic saturated hydrocarbon. Examples are, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, - “(C3-C6)cycloalkenyl”, as used herein, refers to a cyclic non aromatic 25 hydrocarbon comprising at least one unsaturated bond. Examples are, but not limited to, cyclopentenyl and cyclohexenyl, - “(C1-Cx)alkoxy”, as used herein, refers to a O-(C1-Cx)alkyl moiety, wherein alkyl is as defined above, for example (C1-C6)alkoxy. Examples are, but are not limited to, methoxy, ethoxy, 1-propoxy, 2-propoxy, butoxy, pentoxy, 30              - “aryl”, as used herein, refers to a monocyclic aromatic group containing 6 carbon atoms and containing between 0 and 2 heteroatoms, such as nitrogen, oxygen or sulphur, and in particular nitrogen. By way of examples of aryl groups, mention may be made 2019300101   30 Mar 2026 of, but not limited to: phenyl, pyridine, pyrimidine, pyridazine, pyrazine and the like. In the framework of the present invention, the aryl is advantageously phenyl, pyridazine, pyrazine, pyridine, such as 2-pyridine or 3-pyridine and pyrimidine. The aryl is even more advantageously phenyl and pyridine, such as 2-pyridine or 3-pyridine. 5               - a “divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms” as used herein, means a divalent ring consisting of an aromatic ring comprising 5 chains and 1, 2, 3 or 4 heteroatoms selected from nitrogen and oxygen atoms. In one embodiment, it comprises at least 1 heteroatom, and preferably at least one nitrogen atom. In another embodiment, it comprises at least 2 heteroatoms, with for example at least one 10 nitrogen atom. According to a further embodiment, it comprises 2, 3 or 4 nitrogen atoms, preferably 3 nitrogen atoms. According to an even further embodiment, it comprises one nitrogen atom and one oxygen atom or two nitrogen atoms and one oxygen atom. Examples are, but not limited to, divalent triazole, such as 1,2,3- or 1,2,4- triazoles, oxadiazoles, such as 1,2,4- oxadiazole or 1,2,3-oxadiazole and divalent diazoles such as divalent diazole and 15 divalent imidazole. According to a preferred embodiment, such divalent 5-membered heteroaromatic ring comprising 2 or 3 heteroatoms is a divalent triazole. The compounds of formula (I), (Ia), (Ib) and (Id) can comprise one or more asymmetric carbon atoms. They can thus exist in the form of enantiomers or of 20 diastereoisomers. These enantiomers, diastereoisomers and their mixtures, including the racemic mixtures, are encompassed within the scope of the present invention. The compounds of the present invention can be prepared by conventional methods of organic synthesis practiced by those skilled in the art. The general reaction 25 sequences outlined below represent a general method useful for preparing the compounds of the present invention and are not meant to be limiting in scope or utility. The compounds of general formula (I) can be prepared according to scheme 1 below. 2019300101   30 Mar 2026 (A1)or(A2) (III) Scheme 1 The synthesis is based on a coupling reaction starting from a halogeno aromatic compound of formula (III), wherein R, R’, m, m’, ring,        ring, X1, X2, n, Y1, Y2 5 are as defined above and X is a chlorine atom, an iodine atom or a bromine atom. According to one embodiment, procedure (A1) may advantageously be used when the group is in meta or para position on the ring, with respect to the -NH- group. 10              According to procedure (A1), the compound of formula (III) may be placed in a protic solvent such as tert-butanol. The compound of formula (II) may then be added, for example in a molar ratio ranging from 1 to 1.5 with respect to the compound of formula (III) in presence of an inorganic base, such as Cs2CO3 or K2CO3, for example in a molar ratio ranging from 1 to 5 still with respect to the compound of formula (III), in the presence of a 15 diphosphine, such as Xantphos (4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) or X-Phos (2-Dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl) in particular in an amount ranging from 2 mol% to 15 mol% relative to the total amount of compound of formula (III), and in the presence of an organometallic catalyst, such as Pd(OAc)2 or Pd2dba3, in an amount ranging from 2 mol% to 25 mol% relative to the total amount of compound of formula (III). 20 The reaction mixture can then be heated at a temperature ranging from 80 to 130°C, for example at 90°C, and stirred for a time ranging from 15 to 25 hours, for example during 20 hours, under inert gas and for example argon. The reaction mixture can be concentrated under reduced pressure and the residue can be diluted with an organic solvent such as ethyl acetate. The organic phase can be washed with water, decanted, dried over magnesium 25 sulphate, filtered and then concentrated under reduced pressure to give a compound of formula (I). 2019300101   30 Mar 2026 According to one embodiment, procedure (A2) may advantageously be used when the group is in ortho position on the ring, with respect to the -NH- group. According to procedure (A2), the compound of formula (II) may be placed in a 5 polar aprotic solvent such as dimethylsulfoxide. The compound of formula (III) may then be added, for example in a molar ratio ranging from 1 to 1.5 with respect to the compound of formula (II) in presence of an inorganic base, such as Cs2CO3 or K2CO3, for example in a molar ratio ranging from 1 to 5 still with respect to the compound of formula (II), in the presence of a ligand, such as L-proline in particular in an amount ranging from 2 mol% to 10   25 mol% relative to the total amount of compound of formula (II), and in the presence of an organometallic catalyst, such as CuI, in an amount ranging from 2 mol% to 25 mol% relative to the total amount of compound of formula (II). The reaction mixture can then be heated at a temperature ranging from 80 to 130°C, for example at 90°C, and stirred for a time ranging from 15 to 25 hours, for example during 20 hours, under inert gas and for example argon. 15 The reaction mixture can be diluted with an organic solvent such as ethyl acetate. The organic phase can be washed with water, decanted, dried over magnesium sulphate, filtered and then concentrated under reduced pressure to give a compound of formula (I). The starting compounds of formula (II), (III) are available or can be prepared 20 according to methods known to the person skilled in the art. Accordingly, the present invention further relates to the synthesis process for manufacturing new compounds of formula (I), (I), (Ia), (Ib) and (Id) as defined above, more particularly new compounds of formula (Ia), (Ib) or (Id), comprising at least a step of coupling a compound of formula (II) 25 (II) with a compound of formula (III) 2019300101   30 Mar 2026 (III) wherein X1, Y1, R, R’, m, m’, ring, ring, X2, Y2 are as defined above and X is a chlorine atom, an iodine atom or a bromine atom, in presence of an inorganic base and a ligand and in the presence of an organometallic catalyst, to obtain new compounds of formula (I), (I), (Ia), (Ib), or (Id), more particularly new compounds of formula (Ia), (Ib) or (Id). More particularly, compounds of formula (IIa), when used to prepare compounds of formula (Ia), can be prepared according to scheme 2 below. 10 Preparation of (Ila) for (la) 15 20 Scheme 2 Intermediate compounds of formulae (IIa) and (IVa) are useful for preparing compounds of formula (Ia) according to the invention. According to procedure (B), the bromonitrobenzene derivative may be placed in a polar solvent such as N,N-dimethylformamide. A vinylaryl, with aryl having the same meaning as above defined, may then be added, for example in a molar ratio ranging from 1 to 1.5 with respect to the bromonitrobenzene derivative, in presence of an inorganic base, such as sodium acetate or potassium acetate, in particular in a molar ratio ranging from 1 to 3 still with respect to the compound of formula (III), in the presence of a phosphine such as triphenylphosphine, for example in an amount ranging from 5 mol% to 15 mol% relative to the amount of the bromonitrobenzene derivative, and in the presence of an organometallic 2019300101   30 Mar 2026 catalyst such as Pd(OAc)2 or Pd2dba3 in an amount ranging from 2 mol% to 10 mol% relative to the amount of the bromonitrobenzene derivative. The reaction mixture can then be heated at a temperature ranging from 80 to 140°C, for example at 135°C, and stirred for a time ranging from 15 to 30 hours for example 24 hours under inert gas for example argon. The 5 reaction mixture can be concentrated under reduced pressure and the residue can be diluted with an organic solvent such as ethyl acetate. The organic phase can be washed with water, decanted, dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a compound of formula (IVa). According to procedure (C), the compound of formula (IVa) and tin (II) chloride 10 dihydrate, in a ratio ranging from 3 to 8 equivalents, may be placed in a protic solvent such as ethanol. The reaction mixture can then be heated at a temperature ranging from 40 to 80°C, for example at 60°C and stirred for a time ranging from 15 to 25 hours, for example during 20 hours. The mixture can be poured into 1N NaOH aqueous solution and extracted with an organic solvent such as ethyl acetate. The organic phase can then be washed with 15 water and a saturated aqueous solution of brine, dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a compound of formula (IIa). More particularly, intermediate compounds of formula (IIb) (with at least one of W1 or W2 being CH), when used to prepare compounds of formula (Ib), can be prepared according to scheme 3 below. 20 Preparation of (lib) for (lb), with at least (W1 or W2 = CH) Scheme 3 Intermediate compounds of formulae (IIb) and (IVb) are useful for preparing compounds of formula (Ib) according to the invention. According to procedure (D1), the aminopyridine (W1 and W2 = CH), added for 25 example in a molar ratio ranging from 1 to 1.5 with respect to the nitrobenzoyl chloride derivative, may be placed in an aqueous solution of inorganic base such as sodium hydroxide, for example in a molar concentration ranging from 2M to 5M. A polar aprotic 2019300101   30 Mar 2026 solvent such as dichloromethane may be added to the solution, the reaction mixture can be cooled down to 0°C with an ice bath and a solution of the nitrobenzoyl chloride derivative in a polar aprotic solvent such as dichloromethane can be added dropwise. The reaction mixture can then be stirred at room temperature for a time ranging from 15 to 24 hours, for 5 example 18 hours, under inert gas for example argon. The resulting precipitate can be filtered, washed with water and dichloromethane and dried under vacuum overnight to give a compound of formula (IVb). According to procedure (D2), the aminopyrimidine (W1 or W2 = N and the other W1 or W2 = CH), may be placed in a polar aprotic solvent such as dichloromethane. The 10 nitrobenzoyl chloride derivative may then be added, for example in a molar ratio ranging from 1 to 1.5 with respect to the aminopyrimidine, in presence of an organic base such as N,N-diisopropylethylamine or triethylamine, for example in a molar ratio ranging from 1 to 2 still with respect to the aminopyrimidine, in the presence of a nucleophilic catalyst such as dimethylaminopyridine, for example in a molar ratio ranging from 0.1 to 1 still with respect 15 to the aminopyrimidine. The reaction mixture can then be stirred at room temperature for a time ranging from 5 to 20 hours for example 18 hours, under inert gas and for example argon. The organic phase can be washed with water and the resulting precipitate can be filtered, washed with water and dichloromethane and dried under vacuum overnight to give a compound of formula (IVb). 20              According to procedure (C), the compound of formula (IVb) and tin (II) chloride dihydrate in a ratio ranging from 3 to 8 equivalents may be placed in a protic solvent such as ethanol. The reaction mixture can then be heated at a temperature ranging from 40 to 80°C, for example at 60°C and stirred for a time ranging from 15 to 25 hours, for example during 20 hours. The mixture can be poured into 1N NaOH aqueous solution and extracted 25 with an organic solvent such as ethyl acetate. The organic phase can then be washed with water and a saturated aqueous solution of brine, dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a compound of formula (IIb). In the case of X1 being a -NH-CO- group, another route can be followed to 30 prepare compounds of formula (Ib) and is displayed in scheme X below. 2019300101   30 Mar 2026 Scheme X The synthesis starts with a coupling reaction of a halogeno aromatic compound of formula (IIIb) with an aniline derivative (Vb), wherein R, R’, m, m’, X1, X2, n, Y1, Y2 are 5 as defined above and X is a chlorine atom, an iodine atom or a bromine atom, following procedure (A1) or (A2). According to procedure (K), the compound of formula (VIb) may be placed in a protic solvent such as methanol and an aqueous solution of 2M NaOH may be added in a ratio ranging from 3 to 10 equivalents. The reaction mixture can then be heated at a 10 temperature ranging from 50 to 90°C, for example at 80°C and stirred for a time ranging from 1 to 24 hours, for example during 3 hours. The mixture can be concentrated under reduced pressure and, after addition of an aqueous solution of 2M HCl, extracted with an organic solvent such as dichloromethane. The combined organic phases can then be dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a 15 compound of formula (VIIb). According to procedure (L), the compound of formula (VIIb) and the amine derivative Y1-NH2, in a ratio ranging from 1.0 to 3 equivalents, for example 1.2 equivalent, may be placed in an anhydrous polar solvent such as N,N-dimethylformamide. A coupling 2019300101   30 Mar 2026 agent such as HATU may then be added, for example in a molar ratio ranging from 1 to 2 with respect to compound (VIIb), in presence of an organic base such as triethylamine or N,N-diisopropylethylamine, for example in a molar ratio ranging from 2 to 5 still with respect to compound (VIIb). The reaction mixture can then be stirred at room temperature for a time 5 ranging from 5 to 20 hours, for example 16 hours. The reaction can be quenched upon addition of an aqueous solution of 1M hydrochloric acid and the mixture extracted with an organic solvent such as ethyl acetate. The combined organic phases can then be dried over magnesium sulphate, filtered and concentrated under reduced pressure to afford a compound of formula (Ib). 10 More particularly, compounds of formula (IId), when used to prepare compounds of formula (Id), can be prepared according to scheme 5 below. Preparation of (lid) for (Id) Scheme 5 15              Intermediate compounds of formulae (IId), (IVd) and (Vd) are useful for preparing compounds of formula (Id) according to the invention. According to procedure (F), the 1,4-benzenediamine derivative may be placed in a mixture of polar solvents such as N,N-dimethylformamide and tetrahydrofurane, for example in a ratio ranging from 1 / 4 to 1 / 2. Boc2O (Di-tert-butyl dicarbonate) may then be 20 added dropwise, for example in a molar ratio ranging from 0.25 to 0.75 with respect to the 1,4-benzenediamine derivative in presence of an inorganic base, such as Cs2CO3 or K2CO3, aqueous solution with a concentration ranging from 2M to 3M and for example in a molar ratio ranging from 0.5 to 1 still with respect to the 1,4-benzenediamine derivative. The reaction mixture can then be stirred at room temperature for a time ranging from 10 to 70 25 hours, for example during 64 hours, under inert gas and for example argon. The reaction mixture can be concentrated under reduced pressure and the residue can be diluted with an 2019300101   30 Mar 2026 organic solvent such as ethyl acetate. The organic phase can be washed with water, decanted, dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a compound of formula (IVd). According to procedure (G), the amino derivative (IVd) may be placed in a polar 5 aprotic solvent such as dichloromethane. The carboxylic acid derivative may then be added, for example in a molar ratio ranging from 1 to 1.5 with respect to the amino derivative (IVd), in presence of a coupling agent such as EDCI.HCl (1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), for example in a molar ratio ranging from 1 to 3, in presence of an organic base such as N,N-diisopropylethylamine or triethylamine, for 10 example in a molar ratio ranging from 1 to 5 still with respect to the amino derivative (IVd) and in the presence of HOBt (1-Hydroxybenzotriazole hydrate), for example in a molar ratio ranging from 1 to 3 still with respect to the amino derivative (IVd). The reaction mixture can then be stirred at room temperature for a time ranging from 5 to 30 hours for example 24 hours, under inert gas and for example argon. The organic phase can be washed with water, 15   decanted, dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a compound of formula (Vd). According to procedure (H), the compound of formula (Vd) may be placed in a polar aprotic solvent such as dichloromethane. Trifluoroacetic acid may then be added, for example in a molar ratio ranging from 10 to 30 with respect to the amino derivative (IVd). 20 The reaction mixture can be stirred at room temperature for a time ranging from 1 to 7 hours and then cooled down to 0°C with an ice bath. Water and an inorganic base, such as sodium carbonate or potassium carbonate, can be added until reaching pH > 7. The aqueous phase can be extracted with an organic solvent such as dichloromethane. The organic phases can be gathered, dried over magnesium sulphate, filtered and concentrated under reduced 25 pressure to give a compound of formula (IId). The chemical structures and spectroscopic data of some compounds of formula (I) of the invention are illustrated respectively in the following Table I and Table II. Table I 2019300101   30 Mar 2026 96 N H k xkx. / k kk / N. / \ / x n  Y  T\ H              II                      / o   X 97 h r ZI / k ( X 98 zO 4 k / IZ 99 zO 4 kk IZ - ? \ > 100 X NxX\yX / Y 1A XX X-X n^XXnX^ H           1 / --\ N=N  >- 101 hX Nx^^^^-Z^ T 1 X H k     Ajx kk Z N. / N^ H                  II O              1 102 (X N^^y^k^y^'x, / ^ T 1 1 1 h k     / kx kk / N. z\ / N         S H    XX O O          । 103 Xi NxY^^X^YX  r-XXs II 1 \ Il H k     , / kx kk / n. ^x \ / n x / y \ / XY\ H              II                      / o       x_y 104 Xi Nx^k^Y^'Xx'Xx   X\ N^X / Hx / ^ H                  II               ' O 2019300101   30 Mar 2026 105 o NxA\z;>x / -x T 1 1 1 H A      A / n^ / \ / \ N   X   X > H                  II o    AA 106 0™ / /    / - A H   AO A A / N\ / \ ^N. J N^ \ / ^S^ H       \ O O 107 CA- / / / /     x- n X A n^ n         r o 1      h      II < A / A A / N. / / / N. J N   X H                  II O 108 zO 4 4 / IZ / ZI 8 109 Cv^,       / - / N    X A  N^ A        ( N 1                           H                          1             1 A / Ax / A / n. / x ,N. J N   X H                  II O 110 CA-X / /     / - / yH A h Gn / A / A Ax. / n.     ,n. J N N X H                  II O 111 o IZ ZI A> 4 \ z 112 Q IZ ’• ZI A> 4 A 113 A 4 IZ / ZI o \ 2019300101   30 Mar 2026 114 N'       'n'1- , H            1     / --\ NW __ / - (Ib) 14 O N -l       N     ',' O             1 15 o -   -'        N1    '.'        ; O 16 ZI F-; ZI 6 17 N^l O o      9_ / 18 115 9 IZ / =o 9-9 / IZ -o 116 l--<s -s   , A  O^N-n^ 117 [T^ N O AsVs9 A   oA^nh F f F 2019300101   30 Mar 2026 118 A o N                 n            N          n O 119 ° ■ N"\ ° 120 ° ° 121 ° ■ ■     n"n H             1     /    \ ■^N    °H (Id) 32 '°N    ■ V °             1 33 - / IZ IZ w 34 1 ■ °' \'',. H        ° °        । 35 N oN ■ V ° 122 -^0 / - ....... H         I / --\ ■=. y- Table II 2019300101   30 Mar 2026 Ex Characterizations 1 1H NMR (300 MHz, CDCI3) 5 8.61 (d, J = 4.7 Hz, 1H), 7.66 (td, J = 7.7, 1.9 Hz, 1H), 7.60 (d, J = 16.1 Hz, 1H), 7.52 (d, J = 8.6 Hz, 3H), 7.38 (d, J = 8.1 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.25 (d, J = 7.7 Hz, 2H), 7.14 (td, J = 7.7, 1.9 Hz, 1H), 7.10 (d, J = 8.6 Hz, 2H), 7.08 (d, J = 16.1 Hz, 1H), 6.06 (s, 1H), 5.99 (s, 1H), 3.49 (dd, J = 14.7, 5.9 Hz, 2H), 1.71 (dt, J = 13.4, 6.7 Hz, 1H), 1.52 (dd, J = 14.7, 7.0 Hz, 2H), 0.97 (d, J = 6.6 Hz, 6H). 2 1H NMR (300 MHz, CDCI3) 5 8.60 (d, J = 4.0 Hz, 1H), 7.79 - 7.48 (m, 6H), 7.37 (d, J = 7.9 Hz, 1H), 7.22 - 7.03 (m, 6H), 6.14 (m, 1H), 6.00 (s, 1H), 3.48 (dd, J = 13.8, 6.6 Hz, 2H), 1.70 (dt, J = 13.8, 6.6 Hz, 1H), 1.52 (dd, J = 13.8, 6.6 Hz, 2H), 0.96 (d, J = 6.6 Hz, 6H). 3 1H NMR (300 MHz, CDCI3) 5 8.58 (d, J = 4.0 Hz, 1H), 7.86 (d, J = 16.3 Hz, 1H), 7.63 (td, J = 7.7, 1.7 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.42 (d, J = 7.9 Hz, 1H), 7.38 - 7.23 (m, 3H), 7.15 (d, J = 16.3 Hz, 1H), 7.11 - 7.06 (m, 1H), 6.70 (dd, J = 8.3, 2.0 Hz, 1H), 6.63 (d, J = 2.0 Hz, 1H), 6.13 - 6.00 (m, 2H), 3.86 (s, 3H), 3.48 (dd, J = 14.6, 6.0 Hz, 2H), 1.68 (dt, J = 19.9, 6.6 Hz, 1H), 1.51 (dd, J = 14.7, 7.1 Hz, 2H), 0.96 (d, J = 6.6 Hz, 6H). 4 1H NMR (300 MHz, CDCI3) 5 8.60 (d, J = 4.1 Hz, 1H), 7.69 - 7.49 (m, 5H), 7.37 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 7.26 - 7.21 (m, 2H), 7.16 - 7.03 (m, 4H), 6.10 - 5.99 (m, 1H), 5.96 (s, 1H), 3.48 (dd, J = 14.4, 6.0 Hz, 2H), 1.82 - 1.67 (m, 5H), 1.51 (dd, J = 14.7, 7.0 Hz, 2H), 1.33 -1.15 (m, 4H), 0.96 (dd, J = 20.1, 11.4 Hz, 2H). 5 1H NMR (300 MHz, CDCI3) 5 8.59 (d, J = 4.0 Hz, 1H), 7.69 - 7.62 (m, 1H), 7.59 (d, J = 16.2 Hz, 1H), 7.54 - 7.48 (m, 3H), 7.40 - 7.31 (m, 2H), 7.26 - 7.21 (m, 2H), 7.15 - 7.01 (m, 4H), 6.17 - 6.07 (m, 1H), 5.97 (s, 1H), 3.28 (d, J = 6.3 Hz, 2H), 1.05 - 0.93 (m, 10H). 6 1H NMR (300 MHz, d6-DMSO) 5 8.59 (s, 1H), 8.54 (d, J = 3.8 Hz, 1H), 8.40 (t, J = 5.5 Hz, 1H), 7.75 (td, J = 7.7, 1.6 Hz, 1H), 7.60 (dd, J = 8.5, 7.7 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 7.9 Hz, 1H), 7.36 - 7.30 (m, 2H), 7.21 (ddd, J = 12.2, 5.5, 1.6 Hz, 2H), 7.14 (s, 1H), 7.11 (d, J = 8.5 Hz, 2H), 3.26 (dd, J = 13.8, 6.2 Hz, 2H), 1.85 - 1.72 (m, 3H), 1.66 - 1.42 (m, 6H), 1.18 - 0.99 (m, 2H). 13C NMR (75 MHz, d6-DMSO) 5 164.2, 153.6, 147.5, 141.6, 140.9, 134.8, 134.1, 130.1, 127.2, 126.4, 126.0, 122.8, 119.9, 119.8, 117.8, 116.8, 114.5, 114.2, 77.9, 35.5, 33.6, 30.3, 22.8 [M+H]+ = 412.3 7 1H NMR (300 MHz, CDCI3) 5 8.61 (d, J = 4.0 Hz, 1H), 7.70 - 7.63 (m, 1H), 7.60 (d, J = 16.1 Hz, 1H), 7.56 - 7.49 (m, 3H), 7.42 - 7.34 (m, 3H), 7.30 - 7.25 (m, 4H), 7.18 - 7.04 (m, 4H), 6.05 (s, 1H), 3.01 (dd, J = 14.1, 6.7 Hz, 2H), 1.46 - 1.32 (m, 3H), 0.86 (d, J = 6.6 Hz, 6H). 8 1H NMR (300 MHz, CDCI3) 5 8.60 (d, J = 4.3 Hz, 1H), 7.74 - 7.47 (m, 5H), 7.44 - 7.20 (m, 4H), 7.19 - 6.99 (m, 4H), 6.26 (s, 1H), 6.00 (s, 1H), 3.55 (dd, J = 12.5, 6.4 Hz, 2H), 1.60 - 1.47 (m, 2H), 0.84 - 0.67 (m, 1H), 0.59 - 0.43 (m, 2H), 0.21 - 0.07 (m, 2H). 9 1H NMR (300 MHz, d6 -DMSO) 5 8.56 (s, 1H), 8.53 (d, J = 3.9 Hz, 1H), 8.33 (t, J = 5.5 Hz, 1H), 7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.60 (d, J = 16.2 Hz, 1H), 7.55 (d, J = 10.2 Hz, 2H), 7.48 (d, J = 7.9 Hz, 1H), 7.36 - 7.27 (m, 2H), 7.25 - 7.17 (m, 2H), 7.14 (s, 1H), 7.10 (d, J = 8.8 Hz, 2H), 3.16 (dd, J = 13.2, 6.5 Hz, 1H), 2.36 - 2.25 (dt, J = 15.5, 7.6 Hz, 1H), 2.11 - 1.98 (m, 2H), 1.85 - 1.74 (m, 2H), 1.70 - 1.54 (m, 4H). [M+H]+ = 398.0 10 1H NMR (300 MHz, d6 -DMSO) 5 9.44 (s, 1H), 8.55 (d, J = 4.6 Hz, 1H), 8.08 (t, J = 5.9 Hz, 1H), 7.79 - 7.71 (m, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 7.3 Hz, 1H), 7.21 (dd, J = 7.1, 5.2 Hz, 1H), 7.15 (d, J = 16.1 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H), 3.42 - 3.33 (m, 2H), 1.92 - 1.70 (m, 3H), 1.65 - 1.44 (m, 6H), 1.20 - 1.02 (m, 2H). 11 1H NMR (300 MHz, CDCI3) 5 8.59 (d, J = 4.0 Hz, 1H), 7.68 (d, J = 16.2 Hz, 1H), 7.69 - 7.61 (m, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.53 - 7.47 (m, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.29 (dd, J = 5.5, 1.8 Hz, 1H), 7.13 (d, J = 16.4 Hz, 1H), 7.15 - 7.11 (m, 1H), 6.84 - 6.76 (m, 2H), 6.10 (s, 1H), 6.06 (s, 1H), 3.47 (dt, J = 7.4, 5.9 Hz, 2H), 1.77 - 1.68 (m, 4H), 1.51 (dd, J = 14.7, 7.0 Hz, 2H), 1.40 - 1.14 (m, 4H), 1.04 - 0.86 (m, 2H). 2019300101   30 Mar 2026 Ex Characterizations 12 1H NMR (300 MHz, d6-DMSO) 5 8.55 (d, J = 3.8 Hz, 1H), 8.34 (t, J = 5.5 Hz, 1H), 7.76 (td, J= 7.7, 1.8 Hz, 1H), 7.71 (s, 1H), 7.60 (d, J = 16.1 Hz, 1H), 7.53 - 7.40 (m, 3H), 7.41 (d, J = 8.4 Hz, 1H), 7.32 - 7.14 (m, 4H), 7.11 (dd, J = 7.0, 2.3 Hz, 1H), 3.24 (dd, J = 13.9, 6.2 Hz, 2H), 2.26 (s, 3H), 1.84 - 1.71 (m, 3H), 1.61 - 1.44 (m, 6H), 1.17 - 1.01 (m, 2H). [M+H]+ = 426.4 13 1H NMR (300 MHz, d6-DMSO) 5 8.55 (d, J = 4.0 Hz, 1H), 8.32 (t, J = 5.5 Hz, 1H), 7.81 - 7.72 (m, 1H), 7.71 (s, 1H), 7.60 (d, J = 16.0 Hz, 1H), 7.53 - 7.46 (m, 3H), 7.41 (d, J = 8.6 Hz, 1H), 7.31 -7.17 (m, 5H), 7.11 (d, J = 7.0 Hz, 1H), 3.25 (dd, J = 13.6, 6.5 Hz, 2H), 2.26 (s, 3H), 1.61 (dt, J = 13.5, 6.8 Hz, 1H), 1.40 (dd, J = 14.4, 7.0 Hz, 2H), 0.90 (d, J = 6.6 Hz, 6H). [M+H]+ = 400.3 91 1H NMR (300 MHz, CDCI3) 5 8.58 (d, J = 4.0 Hz, 1H), 7.92 (bs, 1H), 7.85 (d, J = 16.4 Hz, 1H), 7.67 - 7.59 (m, 2H), 7.54 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.37 - 7.22 (m, 3H), 7.14 (d, J = 16.4 Hz, 1H), 7.08 (d, J = 4.8 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.63 (d, J = 2.0 Hz, 1H), 5.95 (s, 1H), 3.86 (s, 3H), 3.70 - 3.63 (m, 4H), 3.57 (dd, J = 11.3, 5.8 Hz, 2H), 2.60 - 2.52 (m, 2H), 2.48 (s, 4H), 1.79 (dt, J = 12.3, 6.0 Hz, 2H). [M+H]+ = 473.4 92 1H NMR (300 MHz, CDCI3) 5 8.58 (d, J = 4.0 Hz, 1H), 7.92 (s, 1H), 7.64 (td, J = 7.7, 1.7 Hz, 1H), 7.56 (d, J = 16.1 Hz, 1H), 7.49 (br s, 1H), 7.44 (br s, 1H), 7.38 (br s, 1H), 7.35 (br s, 1H), 7.30 (d, J = 7.6 Hz, 2H), 7.23 (d, J = 8.3 Hz, 1H), 7.13 (d, J = 7.2 Hz, 2H), 7.06 (d, J = 16.1 Hz, 1H), 3.67 -3.61 (m, 4H), 3.55 (dd, J = 11.4, 5.7 Hz, 2H), 2.57 - 2.50 (m, 2H), 2.46 (br s, 4H), 2.28 (s, 3H), 1.77 (dt, J = 12.0, 6.1 Hz, 2H). 93 1H NMR (300 MHz, CDCI3) 5 8.71 (d, J = 1.9 Hz, 1H), 8.47 (dd, J = 4.7, 1.4 Hz, 1H), 7.82 (d, J= 8.0 Hz, 1H), 7.54 (s, 1H), 7.48 (d, J = 8.5 Hz, 2H), 7.40 - 7.37 (m, 2H), 7.31 - 7.23 (m, 2H), 7.12 (d, J = 16.7 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.97 (d, J = 16.4 Hz, 1H), 6.05 (s, 1H), 4.39 (t, J = 6.1 Hz, 1H), 3.00 (dd, J = 14.2, 6.6 Hz, 2H), 1.80 - 1.66 (m, 3H), 1.59 - 1.41 (m, 5H), 1.12 - 0.96 (m, 2H). [M+H]+ = 448.3 94 1H NMR (400 MHz, d6 -DMSO) 5 8.57 (s, 1H), 8.54 (d, J = 3.8 Hz, 1H), 7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.60 (d, J = 16.1 Hz, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 7.9 Hz, 1H), 7.33 (t, J = 7.8 Hz, 1H), 7.23 - 7.18 (m, 2H), 7.12 (d, J = 16.0 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 7.08 - 7.06 (m, 1H), 6.86 (d, J = 7.5 Hz, 1h), 4.56 (br s, 1H), 3.78 (br s, 1H), 3.08 (br s, 1H), 2.80 (br s, 1H), 2.71 - 2.58 (m, 1H), 1.87 (br s, 2H), 1.46 - 1.36 (m, 2H). 95 1H NMR (300 MHz, d6 -DMSO) 5 8.74 (s, 1H), 8.65 (s, 1H), 8.57 (s, 1H), 8.43 (d, J = 2.4 Hz, 1H), 8.38 (t, J = 5.4 Hz, 1H), 7.72 (d, J = 16.2 Hz, 1H), 7.59 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 5.7 Hz, 2H), 7.29 - 7.22 (m, 1H), 7.18 (d, J = 16.1 Hz, 1H), 7.11 (d, J = 8.5 Hz, 2H), 3.26 (dd, J = 13.5, 6.6 Hz, 2H), 1.69 - 1.54 (m, 1H), 1.41 (dd, J = 14.2, 7.0 Hz, 2H), 0.90 (d, J = 6.6 Hz, 6H). [M+H]+ = 387.0 96 1H NMR (300 MHz, d6 -DMSO) 5 8.74 (s, 1H), 8.65 (s, 1H), 8.57 (s, 1H), 8.43 - 8.38 (m, 2H), 7.72 (d, J = 16.4 Hz, 1H), 7.59 (d, J = 7.7 Hz, 3H), 7.33 (br s, 1H), 7.26 - 7.23 (m, 1H), 7.18 (d, J= 16.4 Hz, 1H), 7.11 (d, J = 8.3 Hz, 2H), 3.25 (dd, J = 13.3, 6.6 Hz, 2H), 1.82 - 1.73 (m, 3H), 1.64 -1.41 (m, 6H), 1.09 (t, J = 6.9 Hz, 2H). 97 1H NMR (300 MHz, CDCI3) 5 8.59 (d, J = 3.8 Hz, 1H), 7.65 (t, J = 7.5 Hz, 1H), 7.58 (d, J = 16.0 Hz, 1H), 7.50 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 7.9 Hz, 1H), 7.32 - 7.26 (m, 1H), 7.14 - 7.10 (m, 2H), 7.07 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 16.2 Hz, 1H), 6.94 (d, J = 7.5 Hz, 1H), 5.92 (s, 1H), 3.71 (br s, 2H), 3.38 (br s, 2H), 1.45 (br s, 2H), 1.32 (br s, 2H), 1.00 (s, 6H). 98 1H NMR (300 MHz, CDCI3) 5 8.58 (d, J = 3.9 Hz, 1H), 7.67 - 7.61 (m, 1H), 7.58 (d, J = 16.1 Hz, 1H), 7.49 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 7.9 Hz, 1H), 7.31 - 7.22 (m, 2H), 7.12 (dd, J = 5.3, 3.6 Hz, 3H), 7.06 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 16.2 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.06 (s, 1H), 3.70 (bs, 2H), 3.37 (bs, 2H), 1.74 - 1.63 (m, 8H), 1.56 - 1.38 (m, 4H). 2019300101   30 Mar 2026 Ex Characterizations 99 1H NMR (300 MHz, CDCI3) 5 8.60 (d, J = 4.2 Hz, 1H), 7.71 - 7.62 (m, 2H), 7.58 - 7.51 (m, 3H), 7.37 (d, J = 8.1 Hz, 2H), 7.21 (d, J = 9.0 Hz, 1H), 7.14 (d, J = 6.6 Hz, 2H), 7.13 (s, 1H), 7.08 (d, J = 16.2 Hz, 2H), 6.04 (s, 1H), 2.67 (d, J = 7.0 Hz, 2H), 2.04 (dt, J = 17.0, 6.9 Hz, 1H), 0.98 (d, J= 6.6 Hz, 6H). 100 1H NMR (400 MHz, d6-DMSO) 5 8.74 (d, J = 2.1 Hz, 1H), 8.72 (s, 1H), 8.53 (s, 1H), 8.42 (dd, J = 4.7, 1.5 Hz, 1H), 8.01 (dt, J = 8.0, 1.8 Hz, 1H), 7.61 (t, J = 2.1 Hz, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.44 (t, J = 8.1 Hz, 1H), 7.38 (dd, J = 7.9, 4.8 Hz, 1H), 7.33 (d, J = 16.5 Hz, 1H), 7.29 (dd, J = 8.0, 1.4 Hz, 1H), 7.18 (d, J = 8.6 Hz, 2H), 7.15 (dd, J = 8.0, 1.4 Hz, 1H), 7.12 (d, J = 16.5 Hz, 1H), 2.59 (d, J = 6.9 Hz, 2H), 1.97 (sextuplet, J = 13.5, 6.7 Hz, 1H), 0.94 (d, J = 6.6 Hz, 6H). 101 1H NMR (300 MHz, CDCI3) 5 8.70 (d, J = 2.1 Hz, 1H), 8.46 (dd, J = 4.6, 1.4 Hz, 1H), 7.82 (d, J= 8.0 Hz, 1H), 7.53 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.36 - 7.20 (m, 4H), 7.12 (d, J = 16.3 Hz, 1H), 7.09 (d, J = 8.6 Hz, 2H), 6.95 (d, J = 16.2 Hz, 1H), 6.03 (s, 1H), 5.95 (s, 1H), 3.47 (dd, J = 14.5, 5.8 Hz, 2H), 1.76 - 1.63 (m, 1H), 1.51 (dd, J = 14.7, 7.1 Hz, 2H), 0.96 (d, J = 6.6 Hz, 6H). 102 1H NMR (400 MHz, d6-DMSO) 5 8.74 (bs, 2H), 8.42 (dd, J = 4.7, 1.5 Hz, 1H), 8.01 (dt, J = 8.0, 1.8 Hz, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.52 - 7.49 (m, 2H), 7.45 (t, J = 7.9 Hz, 1H), 7.38 (dd, J = 8.0, 4.8 Hz, 1H), 7.34 (d, J = 16.7 Hz, 1H), 7.29 (dd, J = 8.0, 1.8 Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 7.14 (d, J = 8.6 Hz, 2H), 7.12 (d, J = 16.5 Hz, 1H), 2.78 (dd, J = 14.5, 7.1 Hz, 2H), 1.58 (q, J = 6.7 Hz, 1H), 1.27 (dd, J = 14.5, 7.0 Hz, 2H), 0.80 (d, J = 6.6 Hz, 6H). 103 1H NMR (300 MHz, CDCI3) 5 8.70 (d, J = 1.7 Hz, 1H), 8.46 (dd, J = 4.7, 1.4 Hz, 1H), 7.82 (d, J= 7.9 Hz, 1H), 7.53 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.36 - 7.21 (m, 4H), 7.12 (d, J = 16.1 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 16.4 Hz, 1H), 6.07 (s, 1H), 5.95 (s, 1H), 3.46 (dd, J = 14.4, 6.1 Hz, 2H), 1.89 - 1.76 (m, 3H), 1.68 - 1.48 (m, 6H), 1.22 - 1.08 (m, 2H). 104 1H NMR (300 MHz, CDCI3) 5 8.70 (d, J = 1.6 Hz, 1H), 8.46 (dd, J = 4.7, 1.3 Hz, 1H), 7.81 (d, J= 8.0 Hz, 1H), 7.54 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.38 - 7.22 (m, 4H), 7.12 (d, J = 16.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 16.4 Hz, 1H), 6.14 (bs, 1H), 6.00 (s, 1H), 3.28 (d, J = 6.4 Hz, 2H), 0.99 (s, 9H) 105 1H NMR (300 MHz, CDCI3) 5 8.70 (d, J = 1.7 Hz, 1H), 8.46 (dd, J = 4.5, 1.1 Hz, 1H), 7.81 (d, J= 8.0 Hz, 1H), 7.53 (bs, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.36 - 7.20 (m, 4H), 7.12 (d, J = 16.3 Hz, 1H), 7.09 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 16.4 Hz, 1H), 6.05 (bs, 1H), 6.00 (s, 1H), 3.47 (dd, J = 13.7, 6.7 Hz, 2H), 1.80 - 1.63 (m, 5H), 1.51 (dd, J = 14.5, 7.0 Hz, 2H), 1.27 - 1.19 (m, 4H), 1.00 - 0.90 (m, 2H). 106 1H NMR (400 MHz, d6-DMSO) 5 8.79 (s, 1H), 8.55 (d, J = 3.8 Hz, 1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.62 (d, J = 16.0 Hz, 1H), 7.60 (d, J = 8.6 Hz, 2H), 7.56 (t, J = 5.8 Hz, 1H), 7.52 - 7.49 (m, 2H), 7.45 (t, J = 7.9 Hz, 1H), 7.31 (dd, J = 7.9, 1.9 Hz, 1H), 7.21 (dd, J = 9.1, 4.2 Hz, 2H), 7.19 (d, J = 15.3 Hz, 1H), 7.15 (d, J = 8.5 Hz, 2H), 3.53 - 3.48 (m, 4H), 2.81 (dd, J = 12.8, 6.8 Hz, 2H), 2.26 - 2.19 (m, 6H), 1.52 (p, J = 7.0 Hz, 2H). 107 1H NMR (300 MHz, CDCI3) 5 8.58 (d, J = 3.9 Hz, 1H), 8.29 (d, J = 5.2 Hz, 1H), 8.20 (t, J = 4.6 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 7.58 (d, J = 16.0 Hz, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.35 (d, J = 8.9 Hz, 2H), 7.14 - 7.10 (m, 1H), 7.06 (d, J = 16.1 Hz, 1H), 6.96 (dd, J = 5.2, 1.1 Hz, 1H), 3.65 - 3.59 (m, 4H), 3.54 (dd, J = 11.2, 5.7 Hz, 2H), 2.55 - 2.49 (m, 2H), 2.48 -2.41 (m, 4H), 1.76 (dt, J = 11.8, 5.9 Hz, 2H). 108 1H NMR (400 MHz, d6-DMSO) 5 9.43 (s, 1H), 8.55 (d, J = 3.8 Hz, 1H), 8.16 (t, J = 5.9 Hz, 1H), 7.80 - 7.73 (m, 2H), 7.67 (t, J = 6.4 Hz, 2H), 7.64 - 7.60 (m, 3H), 7.51 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 7.3 Hz, 1H), 7.22 (dd, J = 7.5, 4.8 Hz, 1H), 7.16 (d, J = 16.0 Hz, 1h), 7.03 (d, J = 8.3 Hz, 1h), 3.54 - 3.49 (m, 4H), 3.39 (q, J = 6.6 Hz, 2H), 2.39 - 2.34 (m, 6H), 1.73 (p, J = 6.8 Hz, 2H). 109 1H NMR (300 MHz, CDCI3) 5 8.60 - 8.57 (m, 2H), 8.28 (d, J = 5.2 Hz, 1H), 7.78 (bs, 1H), 7.66 -7.60 (m, 1H), 7.57 (d, J = 16.2 Hz, 1H), 7.51 (s, 4H), 7.36 (d, J = 7.0 Hz, 2H), 7.14 - 7.10 (m, 1H), 7.06 (d, J = 16.1 Hz, 1H), 7.00 (dd, J = 5.2, 1.0 Hz, 1H), 3.53 (dd, J = 10.7, 5.4 Hz, 2H), 3.06 (bs, 1H), 2.54 - 2.39 (m, 10H), 1.75 (q, J = 5.7 Hz, 2H). 110 1H NMR (300 MHz, CDCI3) 5 8.56 (d, J = 3.9 Hz, 1H), 8.14 (t, J = 5.8 Hz, 1H), 7.66 - 7.56 (m, 3H), 7.51 (d, J = 8.5 Hz, 2H), 7.38 - 7.31 (m, 3H), 7.22 (s, 1H), 7.10 (dd, J = 7.9, 4.3 Hz, 1H), 7.06 (d, J = 16.1 Hz, 1H), 6.96 (dd, J = 6.7, 2.4 Hz, 1H), 3.49 (dd, J = 12.6, 6.4 Hz, 2H), 2.48 - 2.36 (m, 10H), 2.19 (s,3H), 1.77 (dt, J = 13.3, 6.5 Hz, 2H). 2019300101   30 Mar 2026 Ex Characterizations 111 1H NMR (300 MHz, CDCI3) 5 8.59 (d, J = 3.8 Hz, 1H), 7.90 (s, 1H), 7.65 (td, J = 7.7, 1.8 Hz, 1H), 7.61 - 7.55 (m, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.39 - 7.28 (m, 3H), 7.25 - 7.20 (m, 1H), 7.14 - 7.11 (m, 1H), 7.08 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 15.9 Hz, 1H), 5.97 (s, 1H), 3.69 - 3.63 (m, 4H), 3.57 (dd, J = 11.3, 5.8 Hz, 2H), 2.59 - 2.51 (m, 2H), 2.48 (s, 4H), 1.79 (dt, J = 12.2, 6.3 Hz, 2H). 112 1H NMR (400 MHz, d6-DMSO) 5 8.56 (s, 1H), 8.54 (d, J = 4.8 Hz, 1H), 8.45 (t, J = 5.4 Hz, 1H), 7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.60 (d, J = 15.8 Hz, 1H), 7.59 (bs, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 7.9 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.32 - 7.30 (m, 1H), 7.25 - 7.23 (m, 1H), 7.22 -7.19 (m, 1H), 7.12 (d, J = 16.0 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 3.27 (dd, J = 12.7, 6.9 Hz, 2H), 2.36 (bs, 6H), 1.73 - 1.63 (m, 2H), 1.53 - 1.47 (m, 4H), 1.43 - 1.38 (m, 2H). 113 1H NMR (400 MHz, d6-DMSO) 5 8.56 (s, 1H), 8.54 (d, J = 4.8 Hz, 1H), 8.45 (t, J = 5.4 Hz, 1H), 7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.60 (d, J = 15.8 Hz, 1H), 7.59 (bs, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 7.9 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.32 - 7.30 (m, 1H), 7.25 - 7.23 (m, 1H), 7.22 -7.19 (m, 1H), 7.12 (d, J = 16.0 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 3.27 (dd, J = 12.6, 6.8 Hz, 2H), 2.42 - 2.25 (m, 10H), 2.15 (s, 3H), 1.67 (p, J = 7.0 Hz, 2H). 114 1H NMR (300 MHz, CDCI3) 5 8.59 (d, J = 3.8 Hz, 1H), 7.96 (s, 1H), 7.65 (t, J = 7.5 Hz, 1H), 7.58 (d, J = 16.0 Hz, 1H), 7.50 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 7.9 Hz, 1H), 7.32 - 7.26 (m, 1H), 7.14 -7.10 (m, 2H), 7.07 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 16.2 Hz, 1H), 6.94 (d, J = 7.5 Hz, 1H), 5.92 (s, 1H), 3.90 (s, 2H), 2.64 (q, J = 7.1 Hz, 5H), 1.13 (t, J = 7.1 Hz, 6H). 14 1H NMR (300 MHz, CDCI3) 5 8.46 (s, 1H), 8.38 (d, J = 8.2 Hz, 1H), 8.31 (d, J = 4.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.75 (t, J = 7.9 Hz, 1H), 7.59 (s, 1H), 7.42 - 7.28 (m, 5H), 7.09 (d, J = 8.3 Hz, 2H), 7.07 - 7.00 (m, 2H), 6.16 (s, 1H), 6.07 (s, 1H), 3.48 (dd, J = 13.7, 6.7 Hz, 2H), 1.75 - 1.64 (m, 1H), 1.52 (dd, J = 14.5, 7.1 Hz, 2H), 0.96 (d, J = 6.6 Hz, 6H). [M+H]+ = 403.1 15 1H NMR (300 MHz, d6 -DMSO) 5 10.46 (s, 1H), 8.83 (s, 1H), 8.44 (t, J = 5.5 Hz, 1H), 8.37 (d, J= 3.8 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.87 - 7.77 (m, 1H), 7.65 (s, 1H), 7.45 - 7.36 (m, 2H), 7.30 (dt, J = 6.5, 2.2 Hz, 1H), 7.15 (d, J = 5.5 Hz, 1H), 7.11 (d, J = 8.7 Hz, 2H), 3.26 (dd, J = 13.7, 6.4 Hz, 2H), 1.87 - 1.72 (m, 3H), 1.67 - 1.40 (m, 6H), 1.07 (m, 2H). 13C NMR (75 MHz, d6 -DMSO) 164.2, 163.5, 150.8, 146.1, 145.3, 140.1, 136.2, 134.3, 128.1, 127.5, 122.3, 119.3, 118.1, 117.6, 117.5, 115.7, 112.8, 112.7, 35.7, 33.7, 30.5, 23.0 [M+H]+ = 429.1 16 1H NMR (300 MHz, d6 -DMSO) 5 10.46 (s, 1H), 8.83 (s, 1H), 8.42 - 8.37 (m, 2H), 8.19 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.82 (t, J = 8.8 Hz, 1H), 7.64 (s, 1H), 7.42 - 7.35 (m, 2H), 7.327..29 (m 1H), 7.17 - 7.13 (m, 1H), 7.10 (d, J = 8.6 Hz, 2H), 3.28 (dd, J = 13.3, 6.8 Hz, 2H), 1.78 -1.57 (m, 5H), 1.43 (dd, J = 14.2, 6.9 Hz, 2H), 1.34 - 1.12 (m, 4H), 0.99 - 0.82 (m, 2H). 17 1H NMR (300 MHz, d6 -DMSO) 5 10.92 (s, 1H), 8.91 (d, J = 8.8 Hz, 2H), 8.68 (d, J = 5.8 Hz, 1H), 8.44 - 8.41 (m, 1H), 8.21 (dd, J = 5.9, 1.3 Hz, 2H), 7.98 (d, J = 8.8 Hz, 2H), 7.66 (s, 1H), 7.47 -7.36 (m, 2H), 7.31 (d, J = 7.2 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 3.27 (dd, J = 13.7, 6.5 Hz, 2H), 1.84 - 1.73 (m, 3H), 1.64 - 1.44 (m, 6H), 1.17 - 1.04 (m, 2H). [M+H]+ = 430.0 18 1H NMR (300 MHz, d6 -DMSO) 5 10.68 (s, 1H), 8.82 (s, 1H), 8.70 (d, J = 4.8 Hz, 2H), 8.39 (t, J = 5.5 Hz, 1H), 7.90 (d, J = 8.7 Hz, 2H), 7.64 (s, 1H), 7.42 - 7.34 (m, 2H), 7.32 - 7.29 (m, 1H), 7.21 (t, J = 4.8 Hz, 1H), 7.09 (d, J = 8.7 Hz, 2H), 3.27 (dd, J = 13.8, 6.4 Hz, 2H), 1.62 (dt, J = 13.3, 6.7 Hz, 1H), 1.42 (dd, J = 14.4, 6.9 Hz, 2H), 0.90 (d, J = 6.6 Hz, 6H). [M+H]+ = 404.0 2019300101   30 Mar 2026 Ex Characterizations 115 1H NMR (400 MHz, d6-DMSO) 5 9.96 (s, 1H), 7.78 - 7.67 (m, 4H), 7.57 (d, J = 2.0 Hz, 1H), 7.33 (t, J = 7.9 Hz, 2H), 7.23 (d, J = 8.5 Hz, 1H), 7.16 (t, J = 8.1 Hz, 1H), 7.07 (t, J = 7.4 Hz, 1H), 6.74 -6.68 (m, 1H), 6.67 (t, J = 2.1 Hz, 1H), 6.48 (dd, J = 8.1, 2.1 Hz, 1H), 3.91 (t, J = 6.5 Hz, 2H), 2.04 - 1.92 (m, 1H), 1.75 - 1.57 (m, 7H), 1.35 - 1.09 (m, 6H), 1.04 - 0.95 (m, 2H), 0.88 (q, J = 10.1, 9.5 Hz, 2H), 0.76 - 0.67 (m, 2H). 13C NMR (151 MHz, d6-DMSO) 5 165.6, 160.0, 146.2, 144.9, 139.9, 131.8, 130.2, 128.9, 126.8, 126.7, 126.4, 123.7, 120.9, 116.2, 111.4, 107.5, 105.3, 68.0, 37.2, 33.7, 33.3, 26.6, 26.6, 26.3, 11.6, 7.8 [M+H]+ = 469.2 116 1H NMR (300 MHz, CDCI3) 5 9.70 (s, 1H), 8.66 (d, J = 4.6 Hz, 3H), 7.74 - 7.71 (m, 2H), 7.52 (d, J = 8.4 Hz, 1H), 7.45 (t, J = 7.8 Hz, 2H), 7.36 (t, J = 7.8 Hz, 1H), 7.04 (t, J = 4.4 Hz, 1H), 6.91 (t, J = 7.5 Hz, 1H), 6.11 (d, J = 5.1 Hz, 1H), 3.45 (dd, J = 14.7, 7.0 Hz, 2H), 1.97 - 1.85 (m, 1H), 1.73 -1.62 (m, 1H), 1.51 (dd, J = 14.7, 7.0 Hz, 2H), 1.12 (q, J = 5.2 Hz, 2H), 0.95 (d, J = 6.6 Hz, 6H), 0.71 (q, J = 5.2 Hz, 2H). [M+H]+ = 444.4 117 1H NMR (300 MHz, CDCI3) 5 9.65 (s, 1H), 8.67 (d, J = 4.9 Hz, 2H), 8.55 (s, 1H), 7.75 - 7.72 (m, 2H), 7.53 (d, J = 8.3 Hz, 1H), 7.45 (t, J = 7.1 Hz, 2H), 7.39 (t, J = 8.0 Hz, 1H), 7.05 (t, J = 4.9 Hz, 1H), 6.93 (t, J = 7.3 Hz, 1H), 6.42 (t, J = 5.7 Hz, 1H), 3.72 (dd, J = 12.6, 6.2 Hz, 2H), 2.56 - 2.39 (m, 2H), 1.97 - 1.85 (m, 1H), 1.17 - 1.08 (q, J = 5.7 Hz, 2H), 0.73 (q, J = 5.7 Hz, 2H). [M+H]+ = 470.3 118 1H NMR (300 MHz, CDCI3) 5 8.83 (s, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.24 (d, J = 4.8 Hz, 1H), 8.07 (t, J = 4.3 Hz, 1H), 7.77 (d, J = 8.5 Hz, 2H), 7.75 - 7.65 (m, 2H), 7.36 - 7.26 (m, 3H), 7.09 - 6.96 (m, 4H), 3.67 - 3.60 (m, 4H), 3.54 (dd, J = 11.1, 5.6 Hz, 2H), 2.54 - 2.47 (m, 2H), 2.44 (bs, 4H), 1.76 (dt, J = 11.6, 5.9 Hz, 2H). 119 1H NMR (300 MHz, CDCI3) 5 8.91 (s, 1H), 8.62 (bs, 1H), 8.36 (d, J = 8.3 Hz, 1H), 8.23 (d, J = 4.1 Hz, 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.74 - 7.64 (m, 2H), 7.43 - 7.38 (m, 1H), 7.35 - 7.27 (m, 2H), 7.10 - 6.97 (m, 4H), 3.51 (dd, J = 10.7, 5.4 Hz, 2H), 2.50 - 2.43 (m, 2H), 2.38 (s, 4H), 1.74 (dt, J = 11.3, 5.8 Hz, 2H), 1.56 - 1.45 (m, 4H), 1.38 (d, J = 4.4 Hz, 2H). 120 1H NMR (300 MHz, CDCI3) 5 8.83 (s, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.24 (d, J = 4.8 Hz, 1H), 8.07 (t, J = 4.3 Hz, 1H), 7.77 (d, J = 8.5 Hz, 2H), 7.75 - 7.65 (m, 2H), 7.36 - 7.26 (m, 3H), 7.09 - 6.96 (m, 4H), 3.54 (dd, J = 11.1, 5.6 Hz, 2H), 2.60 - 2.47 (m, 6H), 2.45 - 2.36 (m, 4H), 2.22 (s, 3H), 1.76 (dt, J = 11.6, 5.9 Hz, 2H). 121 1H NMR (300 MHz, d6-DMSO) 5 10.47 (s, 1H), 8.99 (s, 1H), 8.65 (s, 1H), 8.36 (d, J = 4.0 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.6 Hz, 2H), 7.80 (t, J = 7.0 Hz, 1H), 7.68 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.15 - 7.08 (m, 1H), 5.31 (t, J = 5.6 Hz, 1H), 4.60 (d, J = 5.6 Hz, 2H). [M+H]+ = 470.3 32 1H NMR (300 MHz, CDCI3) 5 9.96 (s, 1H), 8.61 (d, J = 4.7 Hz, 1H), 8.29 (d, J = 7.8 Hz, 1H), 7.90 (td, J = 7.7, 1.4 Hz, 1H), 7.69 (d, J = 8.7 Hz, 2H), 7.48 (dd, J = 7.5, 4.9 Hz, 1H), 7.43 (s, 1H), 7.25 (d, J = 8.5 Hz, 1H), 7.21 - 7.14 (m, 2H), 7.11 (d, J = 8.7 Hz, 2H), 6.19 (s, 1H), 5.97 (s, 1H), 3.45 (dd, J = 13.9, 6.6 Hz, 2H), 1.67 (dt, J = 13.4, 6.6 Hz, 1H), 1.49 (dd, J = 14.8, 7.0 Hz, 2H), 0.94 (d, J = 6.6 Hz, 6H). [M+H]+ = 403.1 33 1H NMR (300 MHz, CDCI3) 5 9.98 (s, 1H), 8.62 (d, J = 4.5 Hz, 1H), 8.30 (d, J = 7.7 Hz, 1H), 7.91 (td, J = 7.7, 1.5 Hz, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.49 (dd, J = 6.9, 5.2 Hz, 1H), 7.43 (s, 1H), 7.33 - 7.25 (m, 2H), 7.19 (d, J = 7.7 Hz, 2H), 7.15 (d, J = 8.7 Hz, 2H), 6.11 (s, 1H), 5.82 (s, 1H), 3.27 (d, J = 6.4 Hz, 2H), 0.98 (s, 9H). [M+H]+ = 403.1 2019300101   30 Mar 2026 Ex Characterizations 34 1H NMR (300 MHz, d6-DMSO) 5 10.59 (s, 1H), 8.74 (d, J = 4.4 Hz, 1H), 8.52 (s, 1H), 8.15 (d, J = 7.7 Hz, 1H), 8.06 (t, J = 7.1 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.71 - 7.63 (m, 1H), 7.48 (t, J = 5.7 Hz, 1H), 7.43 - 7.35 (m, 2H), 7.20 (d, J = 9.6 Hz, 1H), 7.13 (d, J = 8.9 Hz, 3H), 2.75 (dd, J = 13.0, 6.7 Hz, 2H), 1.56 (dt, J = 13.9, 7.0 Hz, 1H), 1.25 (dd, J = 14.2, 7.2 Hz, 2H), 0.79 (d, J = 6.6 Hz, 6H). [M+H]+ = 439.1 35 1H NMR (300 MHz, d6-DMSO) 5 10.54 (s, 1H), 8.74 (d, J = 4.4 Hz, 1H), 8.36 (t, J = 5.4 Hz, 1H), 8.29 (s, 1H), 8.16 (d, J = 7.7 Hz, 1H), 8.07 (td, J = 7.7, 1.5 Hz, 1H), 7.82 (d, J = 8.8 Hz, 2H), 7.71 - 7.62 (m, 1H), 7.51 (s, 1H), 7.34 - 7.20 (m, 2H), 7.16 - 7.10 (m, 3H), 3.25 (dd, J = 13.4, 6.5 Hz, 2H), 1.82 - 1.72 (m, 3H), 1.68 - 1.45 (m, 6H), 1.12 - 1.08 (m, 2H). 13C NMR (75 MHz, d6-DMSO) 5 164.9, 160.5, 148.7, 146.9, 142.6, 137.6, 136.6, 134.5, 130.0, 127.6, 125.3, 120.8, 120.0, 116.7, 116.4, 116.1, 113.1, 35.9, 34.0, 30.7, 23.2 [M+H]+ = 429.1 122 1H NMR (300 MHz, CDCI3) 5 10.01 (s, 1H), 8.63 (d, J = 4.7 Hz, 1H), 8.31 (d, J = 7.7 Hz, 1H), 7.92 (td, J = 7.9, 1.9 Hz, 1H), 7.76 (d, J = 8.7 Hz, 2H), 7.67 (s, 1H), 7.49 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 7.41 (t, J = 2.2 Hz, 1H), 7.35 (t, J = 8.1 Hz, 2H), 7.20 (d, J = 8.9 Hz, 2H), 7.18 -7.14 (m, 1H), 7.03 (dd, J = 8.5, 2.0 Hz, 1H), 5.90 (s, 1H), 2.66 (d, J = 6.8 Hz, 2H), 2.03 (dt, J = 13.3, 6.8 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H). The following examples are provided as illustrations and in no way limit the scope of this invention. The following examples illustrate in detail the preparation of some compounds according to the invention. The structures of the products obtained have been confirmed by 5 NMR analyses. EXAMPLES Example 1: compound (6) in Table I According to procedure (B), 2-vinylpyridine (2.32 mL, 22 mmoles, 1.1 eq.) was 10   placed in N,N-dimethylformamide (20 mL) with 1-bromo-4-nitrobenzene (4 g, 20 mmoles, 1 eq.), NaOAc (3.3 g, 40 mmoles, 2 eq.), Pd(OAc)2 (450 mg, 2 mmoles, 10 mol%), PPh3 (525 mg, 2 mmoles, 10 mol%). The reaction mixture was heated at 135°C and stirred for 16 hours under an inert atmosphere of argon. Upon cooling to room temperature, the reaction mixture was concentrated under reduced pressure and the resulting residue was partitioned 15 between ethyl acetate and water. Upon decantation, the aqueous phase was further extracted with dichloromethane. The organic phases were further washed with water, dried over MgSO4, filtered, gathered and concentrated under reduced pressure to give (E)-2-[2-(4-nitrophenyl)ethenyl]pyridine (1.9 g, 42%). 2019300101   30 Mar 2026 1H NMR (300 MHz, CDCI3) 8 8.65 (d, J = 4.1 Hz, 1H), 8.24 (d, J = 9.0 Hz, 2H), 7.75 - 7.69 (m, 4H), 7.42 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 16.2 Hz, 1H), 7.27 - 7.20 (m, 1H). According to procedure (C), (E)-2-[2-(4-nitrophenyl)ethenyl]pyridine (1.9 g, 8.4 5 mmoles, 1 eq.) and tin (II) chloride dihydrate (9.5 g, 42 mmoles, 5 eq.) were placed in EtOH (84 mL). The reaction mixture was heated at 60 °C and stirred for 88 hours under an inert atmosphere of argon. The reaction mixture was then concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate. The organic phase was washed with a 1N NaOH aqueous solution then with a saturated aqueous solution of brine, dried over 10   MgSO4, filtered and concentrated under reduced pressure to afford (E)-4-[2-(pyridin-2- yl)ethenyl]aniline (1.59 g, 96%). 1H NMR (300 MHz, CDCl3) 8 8.56 (d, J = 4.5 Hz, 1H), 7.62 (td, J = 7.9, 1.8 Hz, 1H), 7.53 (d, J = 16.1 Hz, 1H), 7.40 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 7.9 Hz, 1H), 7.09 (dd, J = 7.0, 4.5 Hz, 1H), 6.98 (d, J = 16.1 Hz, 1H), 6.68 (d, J = 8.5 Hz, 2H), 3.80 (s, 2H). 15 2-Cyclopentylethan-1-amine hydrochloride (3.0 g, 19.1 mmoles, 1.1 eq.) was placed in a 3N NaOH aqueous solution (13 mL) and dichloromethane (3.2 mL) was added to the solution. The reaction mixture was cooled down to 0°C with an ice bath and a solution of 3-bromobenzoyl chloride (2.3 mL, 17.4 mmoles, 1 eq.) in dichloromethane (5.5 mL) was 20 added dropwise. The reaction mixture was then stirred at room temperature for 18 hours under an inert atmosphere of argon. Upon decantation, the organic phase was washed with a saturated aqueous solution of brine, dried over MgSO4, filtered and concentrated under reduced pressure to afford 3-bromo-N-(2-cyclopentylethyl)benzamide (5.1 g, 99%). 1H NMR (300 MHz, CDCl3) 8 7.89 (t, J = 1.7 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.62 (d, J 25   = 8.0 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 6.07 (s, 1H), 3.46 (dt, J = 7.4, 5.9 Hz, 2H), 1.93 - 1.77 (m, 3H), 1.67 - 1.52 (m, 6H), 1.25 - 1.06 (m, 2H). According to procedure (A), a reaction mixture of 3-bromo-N-(2-cyclopentylethyl)benzamide (755 mg, 2.55 mmoles, 1 eq.), (E)-4-[2-(pyridin-2- 30 yl)ethenyl]aniline (500 mg, 2.55 mmoles, 1 eq.), Pd2(dba)3 (233 mg, 255 pmoles, 10 mol%), XPhos (243 mg, 510 pmoles, 20 mol%) and K2CO3 (1.41 g, 10.2 mmoles, 4 eq.) in t-BuOH (10.2 mL) was heated at 90°C and stirred for 20 hours under an inert atmosphere of argon. 2019300101   30 Mar 2026 The reaction mixture was then concentrated under reduced pressure and the resulting residue was diluted with dichloromethane. The organic phase was washed with a saturated aqueous solution of brine, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to afford a fraction 5 which, after trituration in diethyl ether, gave (E)-N-(2-cyclopentylethyl)-3-((4-(2-(pyridin-2-yl)vinyl)phenyl)amino)benzamide (6) (613 mg, 58%). 1H NMR (300 MHz, d6-DMSO) 8 8.59 (s, 1H), 8.54 (d, J = 3.8 Hz, 1H), 8.40 (t, J = 5.5 Hz, 1H), 7.75 (td, J = 7.7, 1.6 Hz, 1H), 7.60 (dd, J = 8.5, 7.7 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 10   7.48 (d, J = 7.9 Hz, 1H), 7.36 - 7.30 (m, 2H), 7.21 (ddd, J = 12.2, 5.5, 1.6 Hz, 2H), 7.14 (s, 1H), 7.11 (d, J = 8.5 Hz, 2H), 3.26 (dd, J = 13.8, 6.2 Hz, 2H), 1.85 - 1.72 (m, 3H), 1.66 -1.42 (m, 6H), 1.18 - 0.99 (m, 2H). 13C NMR (75 MHz, d6-DMSO) 8 164.2, 153.6, 147.5, 141.6, 140.9, 134.8, 134.1, 130.1, 127.2, 126.4, 126.0, 122.8, 119.9, 119.8, 117.8, 116.8, 114.5, 114.2, 77.9, 35.5, 33.6, 30.3, 15   22.8 [M+H]+ = 412.3 Example 2: compound (15) in Table I According to procedure (D1), 2-pyridinamine (4.7 g, 50 mmoles, 1.1 eq.) was 20 placed in a 3N NaOH aqueous solution (56 mL) and dichloromethane (24 mL) was added to the solution. The reaction mixture was cooled down to 0°C with an ice bath and a solution of 4-nitrobenzoyl chloride (8.4 g, 45 mmoles, 1 eq.) in dichloromethane (40 mL) was added dropwise. The reaction mixture was then stirred at room temperature for 18 hours under an inert atmosphere of argon. The resulting precipitate was filtered and washed with water and 25 dichloromethane to afford 4-nitro-N-(pyridin-2-yl)benzamide (6.7 g, 61%). 1H NMR (300 MHz, d6-DMSO) 8 10.91 (s, 1H), 8.80 (s, 1H), 8.52 (d, J = 5.5 Hz, 2H), 8.47 (d, J = 7.9 Hz, 1H), 8.41 (d, J = 7.9 Hz, 1H), 7.86 (t, J = 7.9 Hz, 1H), 7.79 (d, J = 5.5 Hz, 2H). 30              According to procedure (C), 4-nitro-N-(pyridin-2-yl)benzamide (1.5 g, 6.2 mmoles, 1 eq.) and tin (II) chloride dihydrate (7.0 g, 30.8 mmoles, 5 eq.) were placed in EtOH (62 mL). The reaction mixture was heated at 60°C and stirred for 16 hours under an inert atmosphere of argon. The reaction mixture was then concentrated under reduced 2019300101   30 Mar 2026 pressure and the resulting residue was diluted with ethyl acetate. The organic phase was washed with a 1N NaOH aqueous solution then with water, dried over MgSO4, filtered and concentrated under reduced pressure to afford 4-amino-N-(pyridin-2-yl)benzamide (273 mg, 21%). 5   1H NMR (300 MHz, d6 -DMSO) 8 10.44 (s, 1H), 8.44 (d, J = 6.3 Hz, 2H), 7.77 (d, J = 6.3 Hz, 2H), 7.18 (t, J = 7.9 Hz, 1H), 7.12 - 7.03 (m, 2H), 6.78 (d, J = 7.9 Hz, 1H), 5.38 (s, 2H). 2-Cyclopentylethan-1-amine hydrochloride (1.0 g, 7 mmoles, 1.1 eq.) was placed in a 3N NaOH aqueous solution (4.6 mL) and dichloromethane (1.1 mL) was added 10 to the solution. The reaction mixture was cooled down to 0°C with an ice bath and a solution of 3-bromobenzoyl chloride (0.8 mL, 6 mmoles, 1 eq.) in dichloromethane (1.9 mL) was added dropwise. The reaction mixture was then stirred at room temperature for 18 hours under an inert atmosphere of argon. Upon decantation, the organic phase was washed with a saturated aqueous solution of brine, dried over MgSO4, filtered and concentrated under 15   reduced pressure to afford 3-bromo-N-(2-cyclopentylethyl)benzamide (1.77 g, 98%). 1H NMR (300 MHz, CDCl3) 8 7.89 (t, J = 1.7 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 6.07 (s, 1H), 3.46 (dt, J = 7.4, 5.9 Hz, 2H), 1.93 -1.77 (m, 3H), 1.67 - 1.52 (m, 6H), 1.25 - 1.06 (m, 2H). 20              According to procedure (A), a reaction mixture of 3-bromo-N-(2- cyclopentylethyl)benzamide (296 mg, 1.0 mmole, 1 eq.), 4-amino-N-(pyridin-2-yl)benzamide (213 mg, 1.0 mmole, 1 eq.), Pd2(dba)3 (92 mg, 0.1 mmole, 10 mol%), XPhos (95 mg, 0.2 mmole, 20 mol%) and K2CO3 (553 mg, 4.0 mmoles, 4 eq.) in t-BuOH (4 mL) was heated in a microwave reactor at 120°C for 60 minutes. The reaction mixture was then 25   concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate. The organic phase was washed with water, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to give N-(2-cyclopentylethyl)-3-((4-(pyridin-2-ylcarbamoyl)phenyl)amino)benzamide (15) (30 mg, 7%). 30 1H NMR (300 MHz, d6-DMSO) 8 10.46 (s, 1H), 8.83 (s, 1H), 8.44 (t, J = 5.5 Hz, 1H), 8.37 (d, J = 3.8 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.87 - 7.77 (m, 1H), 7.65 (s, 1H), 7.45 - 7.36 (m, 2H), 7.30 (dt, J = 6.5, 2.2 Hz, 1H), 7.15 (d, J = 5.5 Hz, 1H), 2019300101   30 Mar 2026 7.11 (d, J = 8.7 Hz, 2H), 3.26 (dd, J = 13.7, 6.4 Hz, 2H), 1.87 - 1.72 (m, 3H), 1.67 - 1.40 (m, 6H), 1.07 (m, 2H). 13C NMR (75 MHz, d6-DMSO) 8 164.2, 163.5, 150.8, 146.1, 145.3, 140.1, 136.2, 134.3, 128.1, 127.5, 122.3, 119.3, 118.1, 117.6, 117.5, 115.7, 112.8, 112.7, 35.7, 33.7, 30.5, 23.0 5   [M+H]+ = 429.1 Example 3: compound (16) in Table I According to procedure (D1), 2-pyridinamine (5.0 g, 53.1 mmoles, 1 eq.) was placed in a 3N NaOH aqueous solution (65.5 mL) and dichloromethane (5 mL) was added 10 to the solution. The reaction mixture was cooled down to 0°C with an ice bath and a solution of 4-nitrobenzoyl chloride (9.8 g, 53.1 mmoles, 1 eq.) in dichloromethane (70 mL) was added dropwise. The reaction mixture was then stirred at room temperature for 18 hours under an inert atmosphere of argon. The resulting precipitate was filtered and washed with water and dichloromethane to afford 4-nitro-N-(pyridin-2-yl)benzamide (5.8 g, 45%). 15   1H NMR (300 MHz, d6-DMSO) 8 11.16 (s, 1H), 8.40 (dd, J = 4.8, 1.6 Hz, 1H), 8.32 (d, J = 8.9 Hz, 2H), 8.21 (d, J = 9.0 Hz, 2H), 8.17 (d, J = 8.4 Hz, 1H), 7.90 - 7.82 (m, 1H), 7.23 -7.15 (m, 1H). According to procedure (C), 4-nitro-N-(pyridin-2-yl)benzamide (5.8 g, 23.8 20 mmoles, 1 eq.) and tin (II) chloride dihydrate (27 g, 119 mmoles, 5 eq.) were placed in EtOH (240 mL). The reaction mixture was heated at 60°C and stirred for 16 hours under an inert atmosphere of argon. The reaction mixture was then concentrated under reduced pressure and the resulting residue was diluted with dichloromethane. The organic phase was washed with a 1N NaOH aqueous solution then with a saturated aqueous solution of brine, dried 25   over MgSO4, filtered and concentrated under reduced pressure to afford 4-amino-N-(pyridin- 2-yl)benzamide (955 mg, 19%). 1H NMR (300 MHz, d6-DMSO) 8 10.17 (s, 1H), 8.34 (d, J = 3.8 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.80 - 7.75 (m, 3H), 7.09 (dd, J = 6.4, 5.0 Hz, 1H), 6.57 (d, J = 8.6 Hz, 2H), 5.82 (br s, 2H). 30 2-Cyclohexylethan-1-amine (1.1 mL, 7.9 mmoles, 1.1 eq.) was placed in a 3N NaOH aqueous solution (5.3 mL) and dichloromethane (1 mL) was added to the solution. The reaction mixture was cooled down to 0°C with an ice bath and a solution of 3- 2019300101   30 Mar 2026 bromobenzoyl chloride (945 pL, 7.1 mmoles, 1 eq.) in dichloromethane (2.5 mL) was added dropwise. The reaction mixture was then stirred at room temperature for 18 hours under an inert atmosphere of argon. Upon decantation, the organic phase was washed with a saturated aqueous solution of brine, dried over MgSO4, filtered and concentrated under reduced 5 pressure to afford 3-bromo-N-(2-cyclohexylethyl)benzamide (2.0 g, 90%). 1H NMR (300 MHz, CDCh) 8 7.89 (t, J = 1.7 Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 6.00 (bs, 1H), 3.47 (dt, J = 7.5, 5.8 Hz, 2H), 1.81 -1.62 (m, 4H), 1.51 (dd, J = 14.6, 7.1 Hz, 2H), 1.31 - 1.12 (m, 5H), 1.04 - 0.85 (m, 2H). 10              According to procedure (A), a reaction mixture of 3-bromo-N-(2- cyclohexylethyl)benzamide (310 mg, 1.0 mmole, 1 eq.), 4-amino-N-(pyridin-2-yl)benzamide (213 mg, 1.0 mmole, 1 eq.), Pd2(dba)3 (92 mg, 0.1 mmole, 10 mol%), XPhos (95 mg, 0.2 mmole, 20 mol%) and K2CO3 (553 mg, 4.0 mmoles, 4 eq.) in t-BuOH (4 mL) was heated in a microwave reactor at 120°C for 60 minutes. The reaction mixture was then 15   concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate. The organic phase was washed with a saturated aqueous solution of brine, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel and then triturated with diethyl ether to give N-(2-cyclohexylethyl)-3-((4-(pyridin-2-ylcarbamoyl)phenyl)amino)benzamide (16) (78 mg, 20   18%). 1H NMR (300 MHz, d6-DMSO) 8 10.46 (s, 1H), 8.83 (s, 1H), 8.42-8.37 (m, 2H), 8.19 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.82 (t, J = 8.8 Hz, 1H), 7.64 (s, 1H), 7.42 - 7.35 (m, 2H), 7.32-7..29 (m 1H), 7.17 - 7.13 (m, 1H), 7.10 (d, J = 8.6 Hz, 2H), 3.28 (dd, J = 13.3, 25   6.8 Hz, 2H), 1.78 - 1.57 (m, 5H), 1.43 (dd, J = 14.2, 6.9 Hz, 2H), 1.34 - 1.12 (m, 4H), 0.99 - 0.82 (m, 2H). 13C NMR (75 MHz, d6-DMSO) 8 166.4, 165.7, 152.9, 148.3, 147.5, 142.3, 138.4, 136.5, 130.2, 129.7, 124.5, 121.5, 120.3, 119.8, 117.9, 115.0, 114.9, 37.5, 37.1, 35.3, 33.2, 26.5, 26.2 30   [M+H]+ = 429.1 2019300101   30 Mar 2026 Example 4: compound (115) in Table I According to procedure (J), a solution of methyl 4-amino-3-bromobenzoate (3.00 g, 12.8 mmoles, 1 eq.) and potassium cyclopropyltrifluoroborate (2.84 g, 19.2 mmoles, 1.5 eq.) in toluene (52.5 mL) and water (13.5 mL) was degassed with argon during 5 minutes 5 then tripotassium phosphate (6.88 g, 31.9 mmoles, 2.5 eq.), RuPhos (239 mg, 511 pmoles, 0.04 eq.) and palladium(II) acetate (57.9 mg, 256 pmoles, 0.02 eq.) were added. The reaction mixture was heated at 110°C and stirred for 2h30 under inert atmosphere. Upon cooling down to room temperature, it was filtered over a pad of celite and the pad was washed with EtOAc. A saturated aqueous solution of brine was then added to the filtrate and the mixture 10 was extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to give methyl 4-amino-3-cyclopropylbenzoate (2.02 g, 81 %). 1H NMR (400 MHz, d6-DMSO) 8 7.53 (dd, J = 8.4, 2.0 Hz, 1H), 7.42 (d, J = 1.9 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 5.87 (s, 2H), 3.73 (s, 3H), 1.65 (tt, J = 8.3, 5.4 Hz, 1H), 0.95 - 0.82 15   (m, 2H), 0.54 - 0.40 (m, 2H). 3-Bromophenol (701 mg, 3.97 mmoles, 1.2 eq.) was placed in N,N-dimethylformamide (4 mL) with Cs2CO3 (1.30 g, 3.97 mmoles, 1.2 eq.). Upon addition of (3-bromopropyl)cyclohexane (715 mg, 3.31 mmoles, 1.0 eq.), the reaction mixture was 20 stirred for 16 hours under an inert atmosphere of argon. The reaction mixture was partitioned between ethyl acetate and a saturated aqueous solution of NaHCO3. Upon extraction with ethyl acetate, the combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to give 1-bromo-3-(3-cyclohexylpropoxy)benzene (882 mg, 90 %). 25   1H NMR (500 MHz, d6-DMSO) 8 7.22 (t, J = 8.1 Hz, 1H), 7.14 - 7.08 (m, 2H), 6.93 (dd, J = 8.3, 2.3 Hz, 1H), 3.95 (t, J = 6.5 Hz, 2H), 1.68 (tt, J = 15.1, 9.2 Hz, 7H), 1.32 - 1.06 (m, 6H), 0.92 - 0.82 (m, 2H). According to procedure (A), a reaction mixture of 1-bromo-3-(3- 30 cyclohexylpropoxy)benzene (547 mg, 1.84 mmole, 1.1 eq.), methyl 4-amino-3-cyclopropyl-benzoate (320 mg, 1.67 mmol, 1 eq.), BrettPhos Pd G3 (31.9 mg, 33.5 ^mol, 0.02 eq) and Cs2CO3 (818 mg, 2.51 mmol, 1.5 eq.) in anhydrous DMF (8 mL) was degassed with argon and heated at 80°C for 75 minutes under inert atmosphere. The reaction mixture was then 2019300101   30 Mar 2026 cooled down to room temperature, filtered over a pad of celite and the pad was washed with EtOAc. Brine was then added to the filtrate and the mixture was extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to give 5 methyl 4-{[3-(3-cyclohexylpropoxy)phenyl]amino}-3-cyclopropylbenzoate (1.35 g, 80 %). 1H NMR (400 MHz, d6-DMSO) 8 7.82 (s, 1H), 7.66 (dd, J = 8.5, 2.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.24 - 7.14 (m, 2H), 6.76 (d, J = 7.9 Hz, 1H), 6.73 (t, J = 2.1 Hz, 1H), 6.56 (dd, J = 8.1, 2.2 Hz, 1H), 3.92 (t, J = 6.5 Hz, 2H), 3.78 (s, 3H), 1.94 (ddd, J = 13.8, 8.3, 5.4 Hz, 1H), 1.75 - 1.58 (m, 7H), 1.35 - 1.08 (m, 6H), 1.04 - 0.94 (m, 2H), 0.88 (q, J = 10.0, 9.3 10 Hz, 2H), 0.65 - 0.56 (m, 2H). According to procedure (E), methyl 4-{[3-(3-cyclohexylpropoxy)phenyl]amino}-3-cyclopropylbenzoate (575 mg, 1.34 mmole, 1 eq.) was placed in methanol (10 mL) and an aqueous solution of 2M NaOH (4.7 mL, 9.4 mmoles, 7 eq.) was added. The reaction mixture was heated at 80°C and stirred for 3 hours. It was 15 then concentrated under reduced pressure and, after addition of an aqueous solution of 2M HCl (7.0 mL, 14 mmoles, 10.5 eq), extracted with dichloromethane. The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to give 4-{[3-(3-cyclohexylpropoxy)phenyl]amino}-3-cyclopropylbenzoic acid (540 mg, 97 %). 20   1H NMR (400 MHz, d6-DMSO) 8 12.37 (s, 1H), 7.76 (s, 1H), 7.64 (dd, J = 8.5, 2.0 Hz, 1H), 7.52 (d, J = 1.9 Hz, 1H), 7.18 (t, J = 8.6 Hz, 2H), 6.74 (d, J = 7.9 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 6.53 (dd, J = 8.1, 2.1 Hz, 1H), 3.91 (t, J = 6.5 Hz, 2H), 1.94 (ddd, J = 13.6, 8.4, 5.4 Hz, 1H), 1.75 - 1.58 (m, 7H), 1.35 - 1.09 (m, 6H), 0.98 (dd, J = 4.0, 2.0 Hz, 2H), 0.88 (q, J = 10.1, 9.3 Hz, 2H), 0.65 - 0.56 (m, 2H). 25 According to procedure (F), 4-{[3-(3-cyclohexylpropoxy)phenyl]amino}-3-cyclopropylbenzoic acid (50.0 mg, 127 pmoles, 1 eq.) and aniline (12.2 uL, 133 pmoles, 1.05 eq.) were placed in anhydrous N,N-dimethylformamide (650 ^L). HATU (48.3 mg, 127 pmoles, 1 eq.) and DIPEA (44.4 uL, 254 pmoles, 2 eq.) were added and the resulting reaction 30 mixture was stirred at room temperature for 16 hours. The reaction was quenched with 1M aqueous hydrochloric acid and extracted with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The 2019300101   30 Mar 2026 resulting residue was purified by column chromatography on silica gel to give 4-{[3-(3-cyclohexylpropoxy)phenyl]amino}-3-cyclopropyl-N-phenylbenzamide (115) (42.0 mg, 67 %). 1H NMR (400 MHz, d6 -DMSO) 8 9.96 (s, 1H), 7.78 - 7.67 (m, 4H), 7.57 (d, J = 2.0 Hz, 1H), 5   7.33 (t, J = 7.9 Hz, 2H), 7.23 (d, J = 8.5 Hz, 1H), 7.16 (t, J = 8.1 Hz, 1H), 7.07 (t, J = 7.4 Hz, 1H), 6.74 - 6.68 (m, 1H), 6.67 (t, J = 2.1 Hz, 1H), 6.48 (dd, J = 8.1, 2.1 Hz, 1H), 3.91 (t, J = 6.5 Hz, 2H), 2.04 - 1.92 (m, 1H), 1.75 - 1.57 (m, 7H), 1.35 - 1.09 (m, 6H), 1.04 - 0.95 (m, 2H), 0.88 (q, J = 10.1, 9.5 Hz, 2H), 0.76 - 0.67 (m, 2H). 13C NMR (151 MHz, d6-DMSO) 8 165.6, 160.0, 146.2, 144.9, 139.9, 131.8, 130.2, 128.9, 10    126.8, 126.7, 126.4, 123.7, 120.9, 116.2, 111.4, 107.5, 105.3, 68.0, 37.2, 33.7, 33.3, 26.6, 26.6, 26.3, 11.6, 7.8 [M+H]+ = 469.2 Example 5: compound (35) in Table I 15              According to procedure (F), benzene-1,4-diamine (4.0 g, 37 mmoles, 3.0 eq.) was placed in tetrahydrofurane (37 mL) and N,N-dimethylformamide (12 mL). A 2.2M K2CO3 aqueous solution (6.8 mL, 13.6 mmoles, 1.1 eq.) was added to the solution and Boc2O (2.6 mL, 12.3 mmoles, 1.0 eq.) was then added dropwise. The reaction mixture was stirred at room temperature for 64 hours. The reaction mixture was then concentrated under reduced 20 pressure and the resulting residue was diluted with ethyl acetate. The organic phase was washed with water, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to give tert-butyl (4-aminophenyl)carbamate (1.6 g, 62%). 1H NMR (300 MHz, CDCl3) 8 7.13 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 6.32 (s, 25    1H), 3.54 (s, 2H), 1.50 (s, 9H). According to procedure (G), a reaction mixture of tert-butyl (4-aminophenyl)carbamate (1.6 g, 7.7 mmoles, 1.0 eq.), 2-pyridinecarboxylic acid (1.0 g, 8.5 mmoles, 1.1 eq.), EDCI.HCl (1.6 g, 8.5 mmoles, 1.1 eq.), N,N-diisopropylethylamine (3.8 30 mL, 23 mmoles, 3.0 eq.) and HOBt (1.1 g, 8.5 mmoles, 1.1 eq.) in anhydrous dichloromethane (15 mL) was stirred at room temperature for 24 hours under an inert atmosphere of argon. The organic phase was washed with water, dried over MgSO4, filtered 2019300101   30 Mar 2026 and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to give tert-butyl N-[4-(pyridine-2-amido)phenyl]carbamate (983 mg, 41%). 1H NMR (300 MHz, CDCI3) 8 9.98 (s, 1H), 8.61 (d, J = 4.5 Hz, 1H), 8.29 (d, J = 7.7 Hz, 5    1H), 7.91 (td, J = 7.7, 1.5 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.48 (ddd, J = 7.7, 4.5, 1.5 Hz, 1H), 7.40 (d, J = 8.8 Hz, 2H), 6.61 (s, 1H), 1.52 (s, 9H). According to procedure (H), tert-butyl N-[4-(pyridine-2-amido)phenyl]carbamate (983 mg, 3.1 mmoles, 1 eq.) was placed in dichloromethane (6.3 10 mL) and trifluoroacetic acid (5.1 mL, 68.2 mmoles, 22 eq.) was added to the solution. The reaction mixture was stirred at room temperature for 1 hour and then cooled down to 0°C with an ice bath. Water and then K2CO3 were added until reaching pH > 7. The aqueous phase was extracted with dichloromethane. The organic phases were gathered, dried over MgSO4, filtered and concentrated under reduced pressure to give N-(4- 15 aminophenyl)pyridine-2-carboxamide (659 mg, 99%). 1H NMR (300 MHz, CDCl3) 8 9.85 (s, 1H), 8.60 (d, J = 4.5 Hz, 1H), 8.29 (d, J = 7.7 Hz, 1H), 7.89 (td, J = 7.7, 1.5 Hz, 1H), 7.57 (d, J = 8.7 Hz, 2H), 7.46 (ddd, J = 7.7, 4.5, 1.5 Hz, 1H), 6.72 (d, J = 8.7 Hz, 2H), 3.63 (s, 2H). 20              2-Cyclopentylethan-1-amine hydrochloride (1.0 g, 7 mmoles, 1.1 eq.) was placed in a 3N NaOH aqueous solution (4.6 mL) and dichloromethane (1.1 mL) was added to the solution. The reaction mixture was cooled down to 0°C with an ice bath and a solution of 3-bromobenzoyl chloride (0.8 mL, 6 mmoles, 1 eq.) in dichloromethane (1.9 mL) was added dropwise. The reaction mixture was then stirred at room temperature for 18 hours 25 under an inert atmosphere of argon. Upon decantation, the organic phase was washed with a saturated aqueous solution of brine, dried over MgSO4, filtered and concentrated under reduced pressure to afford 3-bromo-N-(2-cyclopentylethyl)benzamide (1.77 g, 98%). 1H NMR (300 MHz, CDCl3) 8 7.89 (t, J = 1.7 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 6.07 (s, 1H), 3.46 (dt, J = 7.4, 5.9 Hz, 2H), 1.93 - 30   1.77 (m, 3H), 1.67 - 1.52 (m, 6H), 1.25 - 1.06 (m, 2H). According to procedure (A), a reaction mixture of 3-bromo-N-(2-cyclopentylethyl)benzamide (296 mg, 1.0 mmole, 1 eq.), N-(4-aminophenyl)pyridine-2- 2019300101   30 Mar 2026 carboxamide (213 mg, 1.0 mmole, 1 eq.), Pd2(dba)3 (92 mg, 0.1 mmole, 10 mol%), XPhos (95 mg, 0.2 mmole, 20 mol%) and K2CO3 (553 mg, 4.0 mmoles, 4 eq.) in t-BuOH (4 mL) was heated in a microwave reactor at 120°C for 60 minutes. The reaction mixture was then concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate. 5 The organic phase was washed with water, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica                gel                to                give                N-(4-((3-((2- cyclopentylethyl)carbamoyl)phenyl)amino)phenyl)picolinamide (35) (89 mg, 21%), upon recrystallisation. 10   1H NMR (300 MHz, d6-DMSO) 8 10.54 (s, 1H), 8.74 (d, J = 4.4 Hz, 1H), 8.36 (t, J = 5.4 Hz, 1H), 8.29 (s, 1H), 8.16 (d, J = 7.7 Hz, 1H), 8.07 (td, J = 7.7, 1.5 Hz, 1H), 7.82 (d, J = 8.8 Hz, 2H), 7.71 - 7.62 (m, 1H), 7.51 (s, 1H), 7.34 - 7.20 (m, 2H), 7.16 - 7.10 (m, 3H), 3.25 (dd, J = 13.4, 6.5 Hz, 2H), 1.82 - 1.72 (m, 3H), 1.68 - 1.45 (m, 6H), 1.12 - 1.08 (m, 2H). 15   13C NMR (75 MHz, d6-DMSO) 8 164.9, 160.5, 148.7, 146.9, 142.6, 137.6, 136.6, 134.5, 130.0, 127.6, 125.3, 120.8, 120.0, 116.7, 116.4, 116.1, 113.1, 35.9, 34.0, 30.7, 23.2 [M+H]+ = 429.1 Pharmacological data 20            Example 6: Chikungunya virus The compounds of the invention have been the subject of pharmacological tests which have demonstrated their relevance as active substances in therapy and in particular for preventing, inhibiting or treating Chikungunya virus infection. 25         MATERIAL AND METHODS Inhibition of Chikungunya virus (CHIKV) production in infected HEK293T cell line. The ability of the compounds to inhibit viral replication was assessed with an experiment in which infected cells were treated by compounds of formula (I) at 1 uM. As a 30 positive control for inhibition of Chikungunya, Ribavirin was used. Toxicity of the compounds was assessed in parallel. 2019300101   30 Mar 2026 • Amplification of cells Human embryonic kidney cells 293T (HEK293T, CRL-11268) were maintained in Dulbecco’s modified Eagle’s Medium (DMEM, 31966-021, Thermo Fisher Scientific) supplemented with 10% of fetal bovine serum (FBS), penicillin and streptomycin. After 5 removal of the medium, cells were washed with Ca2+ and Mg2+-free salt solution to remove all traces of serum. After aspiration of wash solution, cells were dissociated with 0.25% Trypsin-EDTA solution and incubated 30s at least in 37°C incubator. Concentration of cell suspension was determined by an automatic cell counter (EVE, NanoEntek) and, if needed, adjusted to 0.33 x 106 cells / mL with DMEM medium supplemented with 10% FBS. 10 • Preparation of the compounds 100 uL of the cell suspension were dispatched in a ViewPlate-96 Black (6005182, PerkinElmer) and in a transparent 96-well cell culture plate (655180, Greiner bio-one). After an incubation for 24h at 37°C under 5% of CO2, compounds were added at the 15 proper concentration. • Screen at 1 uM An intermediate dilution was prepared with DMSO (D8418, Sigma) at 2 mM in a 96-well V-bottom microplate from the stock solution: 20             Mix 1 uL of the 50 mM stock library in 25 uL of DMSO. Mix 2 uL of the 25 mM stock library in 25 uL of DMSO. • Determination of IC50 values An intermediate dilution was prepared with DMSO (D8418, Sigma) at 25 mM in a 25 96-well V-bottom microplate from the stock solution: Mix 2 uL of the 50 mM stock library in 2 uL of DMSO. Perform serial dilution in 2 uL of DMSO 13 times to reach 0.0015 mM. Proceed as follows in table III: Table III Concentration (mM) Volume     of DMSO 100% (UL) Volume of solution 2019300101   30 Mar 2026 A 12,5 2 2 pL of 50 mM solution B 6,25 2 2 pL of solution A C 3,125 2 2 pL of solution B D 1,56 2 2 pL of solution C E 0,78 2 2 pL of solution D F 0,39 2 2 pL of solution E G 0,195 2 2 pL of solution F H 0,0976 2 2 pL of solution G I 0,0488 2 2 pL of solution H J 0,0244 2 2 pL of solution I K 0,0122 2 2 pL of solution J L 0,0061 2 2 pL of solution K M 0,0030 2 2 pL of solution L N 0,0015 2 2 pL of solution M For both screen and determination of IC50, 1 pL of each solution was added in a 1 mL Masterblock 96 wells (Greiner bio-one, 780261) containing 1 mL of DMEM medium. As a positive control, 5 pL of a 80 mM Ribavirin solution (R9644, Sigma) is added to 1 mL 5   of DMEM. On the other hand, DMSO is used as a negative control. • Infection Cells were infected with 30 pL of CHIKV strain of La Reunion outbreak (LR2006-OPY1) with GFP modification in 5’ (CHIK 5’LR) (Tsetsarkin K, Higgs S, McGee 10 CE, De Lamballerie X, Charrel RN, Vanlandingham DL. Infectious Clones of Chikungunya Virus (La Reunion Isolate - Ref-SKU : 001N-EVA249 (PMID : 17187566) available at the following address: https: / / www.european-virus-archive.com / nucleic-acid / chikv-lr-5gfp-infectious-clone) for Vector Competence Studies. Vector Borne Zoonotic Dis. 2006; 6(4)). This modified virus was used to infect cells at MOI 0.1. The LR2006-OPY1 strain of CHIKV 15 (CHIKV-LR) was obtained from the World Reference Center for Arboviruses at the University of Texas Medical Branch, Galveston, TX. This strain was originally isolated from the serum of a febrile French patient returning from La Reunion Island. 2019300101   30 Mar 2026 • Cell lysis Medium was removed after 22h at 37°C under 5% of CO2 and cells were washed as described above. 60 uL of RIPA buffer (50 mM Tris-HCl pH8, 100 mM NaCl, 1 mM MgCb, 1% Triton X-100) was added to cells and incubated for at least 20 min before reading 5 fluorescence signal. Pierce 660 nm Protein Assay Reagent (22660, Thermo scientific) was used to normalize fluorescence signal by protein quantity. CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) (G3581, Promega) was used to check the toxicity of the compounds. We added 20 uL of MTS solution and read absorbance at 492 nm one hour later. 10 Results - A first round of experiments has been performed wherein the results are expressed as inhibition percentage, which is calculated as follows, through the following steps: 15              1. Fluorescence intensity (FI) / Absorbance 660 nm (A660) = A This ratio allows considering the infection (GFP virus) to the protein amount. 2. A’ = A - background noise of non-infected plate, 3. B = Fluorescence intensity (FI) / Absorbance 660 nm (A660) of infected but non treated plates, 20              4. C = A’ / B, which is then converted as the percentage of infection after treatment, compared to non-treated sample, and subsequently as the infection percentage. For instance, a value of 100 in Table IV here below means that, after treatment, the signal attributed to GFP fluorescence is abolished, which is correlated to the absence of infection. 5. C’ = 100 - C 25              This value corresponds to the inhibition’s percentage. The following Table IV encompasses said C’ value for some compounds, as calculated above with a mean of 2 experiments, and corresponding standard deviation. Some values were originally above 100. In these cases, the value has been lowered to 100. This means that some molecules also have an impact on the viability of the 30   cells. In other words, the A value may be lower than the background noise. Moreover, for each measure, the test was performed with Ribavirin as control. The value of the inhibition percentage was checked, giving 100%. 2019300101   30 Mar 2026 Table IV Ex % CHIKV Inhibition Mean (n = 2) Standard deviation (n = 2) 1 98 3 2 74 28 4 99 2 6 98 3 9 98 2 14 93 7 15 98 1 16 100 0 32 99 2 35 100 0 - A second round of experiments has been performed, giving the results as IC50 5 values. The IC50 values range between 0.1 nM and 1 uM. in particular between 0.5 and 500 nM and even more particularly between 1 and 400 nM, for example between 1 and 200 nM and particularly for compounds 6, 14, 15, 16, 32 and 35 for which the IC50 values range between 200 and 500 nM. For example, compounds 12 and 13 have an IC50 value ranging 10 between 1 and 200 nM. Conclusion Based on the previous results, it can be concluded that the compounds of formula (I) are suitable chemical compounds for treating and / or preventing RNA virus infections 15 caused by RNA viruses of group IV, more particularly, alphavirus infections, and most particularly Chikungunya virus infections. 2019300101   30 Mar 2026 Example 7: RSV virus The compounds of the invention have been the subject of pharmacological tests which have demonstrated their relevance as active substances in therapy and in particular for preventing, inhibiting or treating RSV virus infection. 5 MATERIAL AND METHODS Protocol for screening antiviral compounds for RSV inhibition and cytotoxicity using Viral ToxGlo assay HEp-2 cells were maintained in Eagle’s minimum essential medium (EMEM) 10 with Earle’s BSS adjusted to contain 2mM L-glutamine, 10% fetal bovine serum, 100 U / ml penicillin and 100^g / ml streptomycin. For the purposes of the screening assay they were grown to 90% confluency, trypsinized and recovered. The trypsin was neutralised with cell culture media and cells were centrifuged at 150 x g for 5 minutes before discarding the supernatant and resuspending cell pellet in assay media (EMEM with Earle’s BSS adjusted 15 to contain 2mM L-glutamine, 2% fetal bovine serum and 100 U / ml penicillin and 100ug ml streptomycin). The cells were seeded into white clear-bottomed cell culture plates at a density of 1.5x104 cells / well in 50p.l and 4x103 cells / well in 25pl for 96 well plates and 384 well plates respectively. For the media / background control column assay media only was added. Cell plates were placed in a humid chamber and incubated overnight at 37°C / 5% 20   CO2. After overnight incubation cells were checked for confluency and healthy appearance. Test articles were made up at 10x test concentration in a maximum DMSO concentration of 10% (final assay concentration maximal 1% DMSO) and added to the cell plates in volumes of 10^l for 96 well plates and 5ul for 384 well plates. For cell control and virus control wells the test article solvent only was added. Virus or assay media for 25 cytotoxicity test wells and media / cell control wells was added immediately after test articles at an MOI of 0.5, 40 or 20^l for 96 and 384 well plates respectively. Virus suspension was prepared by thawing RSV A2 frozen stocks and diluting to the required concentration of plaque forming units in assay media on ice. Cell plates were further incubated inside a humid chamber for 72h p.i at 30   37°C / 5%CO2. After the incubation period cells were observed under the microscope to check for characteristic cytopathic effect in virus control wells and healthy cells in the cell control wells. After plates were adjusted to room temperature 20 / 40^l Viral ToxGlo (Promega) was 2019300101   30 Mar 2026 added to each well of the 384 / 96 well cell plates. Plates were incubated at room temperature, protected from light on a plate rocker for 20 minutes before measuring the luminescence on a spectrophotometer (Biotek Synergy HTX). RSV inhibition was calculated as percentage of cytopathic effect inhibition 5 relative to the virus control and cytotoxicity as percentage of cell survival relative to cell control wells. This allowed EC50 values to be calculated for each test article where a virus inhibition or cytotoxic dose response was identified. EC50 values ranging between 0.001 uM and 2.5 uM were found, and more particularly for compound 12, 13, 16 and 115. 10            Table V Ex EC50 (nM) 12 370 < EC50 < 2500 13 370 < EC50 < 2500 16 1168 115 229 Conclusion Based on the previous results, it can be concluded that the compounds of formula (I) are suitable chemical compounds for treating and / or preventing RNA virus infections 15 caused by RNA viruses of group V, more particularly, pneumovirus infections, and most particularly RSV virus infections. Example 8: Dengue 2 virus The compounds of the invention have been the subject of pharmacological tests 20 which have demonstrated their relevance as active substances in therapy and in particular for preventing, inhibiting or treating Dengue 2 virus infection. MATERIAL AND METHODS Protocol for screening antiviral compounds for DENV-2 inhibition and 25 cytotoxicity using Viral ToxGlo assay A549 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U / ml penicillin and 100ug / ml streptomycin. 2019300101   30 Mar 2026 For the purposes of the screening assay they were grown to 90% confluency, trypsinized and recovered. The trypsin was neutralised with cell culture media and cells were centrifuged at 150 x g for 5 minutes before discarding the supernatant and resuspending cell pellet in assay media (DMEM supplemented with 2% fetal bovine serum and 100 U / ml penicillin and 5   100^g / ml streptomycin). The cells were seeded into 96-well white clear-bottomed cell culture plates at a density of 1.0x104 cells / well in 50^l. For the media / background control column assay media only was added. Cell plates were placed in a humid chamber and incubated overnight at 37°C / 5% CO2. After overnight incubation cells were checked for confluency and healthy appearance. 10             Test compounds were prepared at a final concentration of 10 uM in a maximum DMSO concentration of 1% (final assay concentration maximal 0.1% DMSO) and added to the cell plates in volumes of 10ul. For cell control and virus control wells the test article solvent only was added. As a positive inhibition control, 7-Deaza-2'-C-methyladenosine was added at 100 uM in 3 wells. Virus (DENV-2 strain 16681) or assay media for cytotoxicity 15 test wells and media / cell control wells was added immediately after test articles at an MOI of 0.5, 40 for 96 well plates respectively. Virus suspension was prepared by thawing DENV-2 frozen stocks and diluting to the required concentration of plaque forming units in assay media. Cell plates were further incubated inside a humid chamber for 5 days p.i at 20   37°C / 5%CO2. After the incubation period cells were observed under the microscope to check for characteristic cytopathic effect in virus control wells and healthy cells in the cell control wells. After plates were adjusted to room temperature 20ul Viral ToxGlo (Promega) was added to each well of the 96-well cell plates. Plates were incubated at room temperature for 5 minutes before measuring the luminescence on a spectrophotometer (Envision, 25 PerkinElmer). DENV-2 inhibition was calculated as percentage of cytopathic effect inhibition relative to the virus control and cytotoxicity as percentage of cell survival relative to cell control wells. 2019300101   30 Mar 2026 Table VI Ex % DENV-2 Inhibition Mean (n = 3) 12 96 13 86 15 107 35 66 Conclusion Based on the previous results, it can be concluded that the compounds of formula 5   (I) are suitable chemical compounds for treating and / or preventing RNA virus infections caused by RNA viruses of group IV, more particularly, flavivirus infections, and most particularly Dengue 2 virus infections. The present invention further relates to a pharmaceutical composition 10 comprising at least one new compound as defined above or any of its pharmaceutically acceptable salts, or at least any of compounds (3) to (18), (32) to (35), (91) to (125) as defined above or any of its pharmaceutically acceptable salts and also at least one pharmaceutically acceptable excipient. Pharmaceutical compositions of the invention can contain one or more 15 compound(s) of the invention in any form described herein. Still a further object of the present invention consists of the use of at least one compound of formula (I), as defined above, and compounds (1) to (18) and (32) to (35) and (91) to (122) as defined above, or one of their pharmaceutically acceptable salts according to the present invention for preparing a drug to prevent or treat, in a subject, a RNA virus 20 infection caused by a RNA virus from group IV or Group V according to the Baltimore classification, and for example a Chikungunya infection, a Dengue infection, an Influenza infection or a RSV infection. Therefore, the present invention relates to one compound of formula (I), as defined above, and compounds (1) to (18) and (32) to (35) and (91) to (122) or one of their 25 acceptable salts as an agent for inhibiting, preventing or treating a RNA virus infection, and 2019300101   30 Mar 2026 most preferably a RNA virus infection from group IV or V, and for example a Chikungunya infection, a Dengue infection, an Influenza infection or a RSV infection. According to a particular embodiment, the treatment is continuous or non-5 continuous. A “continuous treatment” means a long-term treatment which can be implemented with various administration frequencies, such as once every day, every three days, once a week, or once every two weeks or once every month. According to one embodiment, the compound of formula (I), or anyone of its 10 pharmaceutically acceptable salts, is administered at a dose varying from 0.1 to 1000 mg, in particular varying from 0.1 to 10 mg, or for example varying from 10 to 200 mg, or for example varying from 200 to 1000 mg. Another object of the invention relates to a therapeutic method for treating and / or 15 preventing a subject from a RNA virus infection, and most preferably a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification comprising the administration of a therapeutically effective quantity of a compound of formula (I), compounds (1) to (18) and (32) to (35) and (91) to (122), as defined above, or one of their acceptable salts. 20 In a specific embodiment, the invention provides a use of a compound of formula (I) according to the invention or a pharmaceutically acceptable salt thereof or a pharmaceutically active derivative thereof or a method according to the invention wherein the compound of formula (I) is to be administered in combination with a co-agent useful in 25 the treatment of said RNA virus infection, and most preferably said RNA virus infection from group IV or V, and for example Chikungunya infection, Dengue infection, Influenza infection or RSV infection. The compounds can be administered through any mode of administration such 30 as, for example, intramuscular, intravenous, intranasal or oral route, etc. Compounds of the present invention may, in appropriate cases, be administered as prodrugs, such as esters, of compounds with which the invention is concerned. “Prodrug” 2019300101   30 Mar 2026 means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of the present invention. For example, an ester prodrug of a compound of the present invention may be convertible by hydrolysis in vivo to the parent molecule. Suitable esters of compounds of the present invention are for example acetates, 5 citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-p-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates,   benzenesulphonates,   p- toluenesulphonates, cyclohexylsulfamates and quinates. Examples of ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res., 1987, 18, 379. As used herein, 10 references to the compounds of the present invention are meant to also include any prodrug or metabolite forms. The inventive composition can further include one or more additives such as diluents, excipients, stabilizers and preservatives. Such additives are well known to those 15 skilled in the art and are described notably in “Ullmann's Encyclopedia of Industrial Chemistry, 6th Ed.” (various editors, 1989-1998, Marcel Dekker) and in “Pharmaceutical Dosage Forms and Drug Delivery Systems” (ANSEL et al., 1994, WILLIAMS & WILKINS). The aforementioned excipients are selected according to the dosage form and the 20 desired mode of administration. According to another embodiment, pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the 25 infection being treated. Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, 30 intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions 2019300101   30 Mar 2026 may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that 5 may be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Compositions of this invention may be administered in any manner, including, but not limited to, orally, parenterally, sublingually, transdermally, vaginally, rectally, transmucosally, topically, intranasally via inhalation, via buccal or intranasal administration, 10 or combinations thereof. Parenteral administration includes, but is not limited to, intravenous, intra-arterial, intra-peritoneal, subcutaneous, intramuscular, intra-thecal, and intra-articular. The compositions of this invention may also be administered in the form of an implant, which allows slow release of the compositions as well as a slow controlled i.v. infusion. 15              For example, a compound of formula (I) can be present in any pharmaceutical form which is suitable for enteral or parenteral administration, in association with appropriate excipients, for example in the form of plain or coated tablets, hard gelatine, soft shell capsules and other capsules, suppositories, or drinkable, such as suspensions, syrups, or injectable solutions or suspensions, in doses which enable the daily administration of from 20   0.1 to 1000 mg of active substance. In a particular embodiment, a compound of formula (I) according to the invention is administered orally. Oral route of administration is in particular preferred in the prophylaxis or treatment aspect of the invention.

Claims

5               1. A method for treating and / or preventing a subject from a RNA virus infectioncaused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, anInfluenza viral infection and a Dengue viral infection, comprising the administration to a 10 patient in need thereof of a therapeutically effective quantity of a compound of formula (I):(I)wherein:ring independently mean a phenylene or a pyridylene group,15   X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group,Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group,20 X2 representsa -O- group,a-CO-NH- group,a -NH-CO-NH- group,a -OCH2- group,25 a -NH-CO- group,a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatomsor2019300101   30 Mar 2026a -SO2-NH- group,n is 0, 1, 2 or 3,5 m and m’ are independently 0, 1 or 2,Y2 representsa hydrogen atom,a hydroxyl group,10 a morpholinyl group,a piperidinyl group, optionally substituted by a (C1-C4)alkyl group,a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,ora -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a 15 fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 andR3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally substituted by one or two (C1-C4)alkyl group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom,20or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or by a trifluoromethyl group,25R and R’ independently representa (C1-C4)alkyl group,a (C3-C6)cycloalkyl group,a halogen atom,30 a (C1-C5)alkoxy group,a -SO2-NRaRb group,a -SO3H group,2019300101   30 Mar 2026a -OH group, ora -O-SO2-ORc group,Ra, Rb, Rc and Rd independently represent a hydrogen atom or a (C1-C4)alkyl group,5 provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group optionally substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group,10               or any of its pharmaceutically acceptable salt.

2. The method according to claim 1, wherein15ring both represent a phenylene group orpyridylene group andring represents a phenylene group.ring represents a3. The method according to claim 1 or 2, whereinY1 representsa 2-pyridinyl group or a 3-pyridinyl group,20 a pyrimidinyl group or a pyrazinyl group, with one of the nitrogen atoms being in ortho position with respect to X1,provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group,or any of its pharmaceutically acceptable salt.25              4. The method according to claim 1 or 2, whereinX2 representsa -O- group,a-CO-NH- group,a divalent triazole,2019300101   30 Mar 2026ora -SO2-NH- group,or any of its pharmaceutically acceptable salt.5               5. The method according to any one of the claims 1 to 4, whereinY2 representsa hydroxyl group,a morpholinyl group,a piperidinyl group, optionally substituted by a (C1-C4)alkyl group,10 a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,ora -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a15   (C3-C8)cycloalkyl group,or any of its pharmaceutically acceptable salt.

6. The method according to any one of the claims 1 to 5, wherein0 0ring and ring both represent a phenylene group,20   Y1 represents a 2-pyridinyl group provided that when X1 is a -NH-CO- group, Y1 may furtherbe a phenyl group,X2 represents a -O- group, a-CO-NH- group,Y2 representsa -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, or a 25   (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogenatom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group and R3 represents a hydrogen atom or a (C1-C4)alkyl group, ora morpholinyl group, andR and R’ independently represent a hydrogen atom, (C1-C4)alkyl group, or a 30   (C3-C6)cycloalkyl group,or any of its pharmaceutically acceptable salt.2019300101   30 Mar 202615whereinY1, R, R’, m, m’,102(Ia)7. A method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection, comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound of formula (Ia)ring, X2, n and Y2 are as defined in any one of claims 1 to 5,or any of its pharmaceutically acceptable salt.

8. The method according to claim 7, whereinring is a phenylene group or a pyridylene group,Y1 represents a 2-pyridyl group, a 3-pyridyl group or a pyrazinyl group,n is 1, 2 or 3, m is 0,R’ is a halogen atom, a (C1-C2)alkoxy group or a (C1-C2)alkyl group,X2 represents a -CO-NH- group, a -SO2NH- group or a divalent triazole,Y2 represents20          a morpholinyl group, a piperidinyl group or a piperazinyl group, optionallysubstituted by a (C1-C4)alkyl group,a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl 25 group,2019300101   30 Mar 2026or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or by a trifluoromethyl group,5               or any of its pharmaceutically acceptable salt.

9. A method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein theRNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore10 classification is chosen among a RSV viral infection, a Chikungunya viral infection, anInfluenza viral infection and a Dengue viral infection, comprising the administration to apatient in need thereof of a therapeutically effective quantity of a compound of formula (Ib)15(Ib)whereinY1, R, R’, m, m’,ring, X2, n and Y2 are as defined in any one of claims 1 to 5,or any of its pharmaceutically acceptable salt.

10. The method according to claim 9, whereinring is a phenylene group,20Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen atomof the pyrimidinyl group being in the ortho position with respect to the -NH-CO-group, n is 1, 2 or 3, m is 0, m’ is 0 or 1,R’ is a (C3-C6)cycloalkyl group,X2 represents a -CO-NH- group, a -O- group or a divalent triazole, 25   Y2 representsa hydroxyl group,2019300101   30 Mar 2026a morpholinyl group, a piperidinyl group or a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen5 atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom,or any of its pharmaceutically acceptable salt.10              11. A method for treating and / or preventing a subject from a RNA virusinfection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of theBaltimore classification is chosen among a RSV viral infection, a Chikungunya viralinfection, an Influenza viral infection and a Dengue viral infection, comprising the15 administration to a patient in need thereof of a therapeutically effective quantity of acompound of formula (Id)wherein(Id)Y1, R, R’, m, m’,ring, X2, n and Y2 are as defined in claim 1,20               or any of its pharmaceutically acceptable salt.

12. The method according to claim 11whereinring is a phenylene group,25Y1 represents a 2-pyridyl group or a 3-pyridyl group,X2 represents a -CO-NH- group, a -SO2-NH- group or a divalent triazole,m’ and m are 0, n is 1, 2 or 3,2019300101   30 Mar 2026Y2 represents a hydroxyl or a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group,5 or any of its pharmaceutically acceptable salt.

13. A method for treating and / or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the10 Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection, comprising the administration to a patient in need thereof of a therapeutically effective quantity of acompound selected from99 98 97 96 95 94 93 / / N'N \__ /   1         H VCUa 1 IZ .: '1 4 / IZ - ZpZ IZ ZI J 0              1 "' 'Xc,r " 0 / ^1      o 0 /                   \\ / / H \ H IJ LA LJo O'2019300101   30 Mar 2026100 / ZI x=Z 101 N1 X; ,h O              1 102 NX X H H O O          । 103 z=\ 4 / IZ -- zz 104 N1 Vv 1 O 105 □ ZI ( z 106 H           '' \\ O O2019300101   30 Mar 2026107 N          tT         N n                 \ O H                           1             1 kA. A kk / N\    / N. k n        >r H                  II O 108 ■         :.N     N O 109 N      >k ^1   N^?           r N 1                           H                          1             1 k A Askk / N. / -. ,N. J N        Xf H                  || O 110 Ck-^       / - / N     A h o k A zk kk / N.     / N. k N N XT H                  II O 111 t'Nk3^£XB^^ O 112 Q IZ ZI k> 4 \ z 113 kk 4 yk IZ - ZI o \ 114 k ZI (Ib)o sO2019300101   30 Mar 2026122 ^IHUXl. N         N NX   H        1 / A N n y-(2) a compound of formula (Ib) as defined in claim 9 or 102019300101   30 Mar 2026(Ib)N HR'm'RmOwhereinn, X2, Y2, R, R’, m, m’ and Z ring are as defined in claim 1,Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen of the pyrimidinyl group being in the ortho position with respect to the -NH-CO-group, with the proviso that the following compound is excluded:(3) a compound of formula (Id) as defined in claim 11 or 1210whereinn, X2, Y2, R, R’, m, m’ and Z ring are as defined in claim 1,Y1 is a 2-pyridyl group,with the proviso that the following compound is excluded:1515.A compound of formula (Ia), (Ib) and (Id) as defined in claim 14 orany of its pharmaceutically acceptable salts, or any of compounds (3) to (18), (32) to (35), (91) to (122) as defined in claim 13 or any of its pharmaceutically acceptable salts, for use as a medicament.2019300101   22 Jun 202616. A compound as defined in claim 13 with the exclusion of compoundsNo 1 and 2, as well as their pharmaceutically acceptable salts.5              17. A pharmaceutical composition comprising at least one compound asdefined in claim 16 or any one of its pharmaceutically acceptable salts, or at least any of compounds (3) to (18), (32) to (35), (91) to (122) as defined in claim 13 or any of its pharmaceutically acceptable salts and also at least one pharmaceutically acceptable excipient.1018. Synthesis process for manufacturing compounds of formula (Ia), (Ib),and (Id) as defined in claim 14, comprising at least a step of coupling a compound of formula(II)(II) with a compound of formula (III)15(III)wherein X1, Y1, R, R’, m, m’, n,ring, X2, Y2 are as definedin claim 14 and X is a chlorine atom, an iodine atom or a bromine atom, in presence of an inorganic base and a diphosphine and in the presence of an organometallic catalyst, to obtaina compound of formula (Ia), (Ib) or (Id) as defined in claim 14.2019. Use, in the manufacture of a medicament for the treatment or prevention of a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a2019300101   30 Mar 2026Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection, of acompound of formula (I):(I)wherein:ring independently mean a phenylene or a pyridylene group,X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group,Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl 10 group,X2 representsa -O- group,a-CO-NH- group,15 a -NH-CO-NH- group,a -OCH2- group,a -NH-CO- group,a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms or20     a -SO2-NH- group,n is 0, 1, 2 or 3,m and m’ are independently 0, 1 or 2,25Y2 represents a hydrogen atom,2019300101   30 Mar 2026a hydroxyl group,a morpholinyl group,a piperidinyl group, optionally substituted by a (C1-C4)alkyl group,a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,5 ora -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally substituted by one 10 or two (C1-C4)alkyl group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl group being optionally interrupted on said R1 and / or R2 by an oxygen atom,or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by 15 one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or by a trifluoromethyl group,R and R’ independently representa (C1-C4)alkyl group,20 a (C3-C6)cycloalkyl group,a halogen atom,a (C1-C5)alkoxy group,a -SO2-NRaRb group,a -SO3H group,25 a -OH group, ora -O-SO2-ORc group,Ra, Rb, Rc and Rd independently represent a hydrogen atom or a (C1-C4)alkyl group,provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group optionally 30 substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group,2019300101   30 Mar 2026a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group ora -O-P(=O)-(ORc)(ORd) group,or any of its pharmaceutically acceptable salt.

20. Use according to claim 19, whereinring both represent a phenylene group orring represents apyridylene group andring represents a phenylene group.

21. Use according to any one of claim 19 or 20, whereinY1 represents10 a 2-pyridinyl group or a 3-pyridinyl group,a pyrimidinyl group or a pyrazinyl group, with one of the nitrogen atoms being in ortho position with respect to X1,provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group, or any of its pharmaceutically acceptable salt.1522. Use according to any one of claims 19 to 21, whereinX2 representsa -O- group,a-CO-NH- group,20 a divalent triazole,ora -SO2-NH- group,or any of its pharmaceutically acceptable salt.25              23. Use according to any one of the claims 19 to 22, whereinY2 representsa hydroxyl group,a morpholinyl group,a piperidinyl group, optionally substituted by a (C1-C4)alkyl group,2019300101   30 Mar 2026a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,ora -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and5   R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a(C3-C8)cycloalkyl group,or any of its pharmaceutically acceptable salt.

24. Use according to any one of the claims 19 to 23, whereinO 010          ring and ring both represent a phenylene group,Y1 represents a 2-pyridinyl group provided that when X1 is a -NH-CO- group, Y1 may further be a phenyl group,X2 represents a -O- group, a-CO-NH- group,Y2 represents15   a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, or a(C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group and R3 represents a hydrogen atom or a (C1-C4)alkyl group, or a morpholinyl group, and20 R and R’ independently represent a hydrogen atom, (C1-C4)alkyl group, or a (C3-C6)cycloalkyl group,or any of its pharmaceutically acceptable salt.

25. Use a compound of formula (Ia)25(Ia)wherein2019300101   30 Mar 2026Y1, R, R’, m, m’,       ring, X2, n and Y2 are as defined in any one of claims 1 to 5,or any of its pharmaceutically acceptable salt,in the manufacture of a medicament for the treatment or prevention of a RNAvirus infection caused by a virus belonging to group IV or V of the Baltimore classification, 5 wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of theBaltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection.26.Use according to claim 25, wherein10ring is a phenylene group or a pyridylene group,Y1 represents a 2-pyridyl group, a 3-pyridyl group or a pyrazinyl group,n is 1, 2 or 3, m is 0,R’ is a halogen atom, a (C1-C2)alkoxy group or a (C1-C2)alkyl group,X2 represents a -CO-NH- group, a -SO2NH- group or a divalent triazole,15   Y2 representsa morpholinyl group, a piperidinyl group or a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen 20 atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkylgroup,or alternatively X2-Y2 represents a group -C(=O)-NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or 25 by a trifluoromethyl group,or any of its pharmaceutically acceptable salt.27.Use of a compound of formula (Ib)2019300101   30 Mar 20262(Ib)whereinY1, R, R’, m, m’,ring, X2, n and Y2 are as defined in any one of claims 1 to 7,or any of its pharmaceutically acceptable salt,5              in the manufacture of a medicament for the treatment or prevention of a RNAvirus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection.1028. Use according to claim 27, whereinring is a phenylene group,Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen atomof the pyrimidinyl group being in the ortho position with respect to the -NH-CO-group,15 n is 1, 2 or 3, m is 0, m’ is 0 or 1,R’ is a (C3-C6)cycloalkyl group,X2 represents a -CO-NH- group, a -O- group or a divalent triazole,Y2 representsa hydroxyl group,20 a morpholinyl group, a piperidinyl group or a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,a -CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl 25 group, said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and / or R2 by anoxygen atom,2019300101   30 Mar 2026or any of its pharmaceutically acceptable salt.

29. Use of a compound of formula (Id)(Id)whereinY1, R, R’, m, m’,ring, X2, n and Y2 are as defined in claim 1 or 2,or any of its pharmaceutically acceptable salt,in the manufacture of a medicament for the treatment or prevention of a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, 10 wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection.

30. Use according to claim 2915whereinring is a phenylene group,Y1 represents a 2-pyridyl group or a 3-pyridyl group,X2 represents a -CO-NH- group, a -SO2-NH- group or a divalent triazole,m’ and m are 0, n is 1, 2 or 3,Y2 represents a hydroxyl or a -CR1R2R3 group, wherein R1, R2 and R3 independently20 represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group,or any of its pharmaceutically acceptable salt,in the manufacture of a medicament for the treatment or prevention of a RNA virus infection 25 caused by a virus belonging to group IV or V of the Baltimore classification, wherein theRNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore2019300101   30 Mar 2026classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection.

31. Use, in the manufacture of a medicament for the treatment or5 prevention of a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is chosen among a RSV viral infection, a Chikungunya viral infection, an Influenza viral infection and a Dengue viral infection, of a compound selected from1 zO O’ ZEZ - ZI 2 - ZI / k 3 N '             li                                 il H kXx A k. N\   / N H                II O              1 4 O H k^k k<^kk ,- N\ n    yy   X y H                II O     k^k 5 N H                  II               ' O 6 N^Xk O h k^k k^kk . N\ n     yf     t^\ H              II                      / O       1— / 7 CX_ n          Ti X r ii H ..-   ,-   ,-N^        / \_-- n      >x - y H H        O O         । 8 ^kk ki h kk\ zkkk -N\ N   X H          II           V O2019300101   30 Mar 20262019300101   30 Mar 20262019300101   30 Mar 2026102 o nA\XX / Y   / / T I I 1 h N. n \ / ^S^ \ / H O O          । 103 z=\ L# 4 4 / IZ - zz 104 '■'" H   , H O 105 o N^A^X / ^ T 1 11 H L / X / X JL N^ / \ / \ N     V     T > H           H o    AX 106 n^^^^ rXi     rY LX XL. n,^X..j N H         / / \ / O O 107 Cv^,       / - n X X n^ X        r o 1                           H                           1             1 X / >L / Xs. / X / N.      / N. L N     V H                  II O 108 N"^nx a h   xO X / >L / ¼ JL N.     / N. L N N V H                  II O 109 (1- / -. / / / - / n    VX n^X        r n 1      H      II X xX\ / Xs X / N. / \ .N. J N H                  II O2019300101   30 Mar 2026110 ' ■ O 111 O 112 O 113 N                         N                                          ' O 114 "'                      .'      'n H            1     /   \ N^N __.N— (Ib) 14 O .'          .            . O             1 15 ZI -- ZI 6 16 ZI ZI 6 17 N^1 O N^AA-o2019300101   30 Mar 202618 [f^ N O 115 P IZ / =° MJ IZ - o 116 l’’»,\? A  O'"^^ 117 "'HO V,' △  O^NH F f F 118 mm o P^JO^O 0 119 mm o ^A^ / ^^NO 0 120 mm o PAnPyN^O'' 02019300101   22 Jun 2026121 o n / \-x^n^\__^ H                1 N^N    oh (Id) 32 ^XXXXh O              Jk. .N.      / n H                II O             1 33 Yin h , 0          N           N H                  II               ' 0 34 ^XXZl h o        xA>.X zNv / \ / N^   ^Sx   Y H        0 0        1 35 Yin h 0 k .X- >Xx J< / N. N   Y   T^\ H              II                      / 0       1— / 122 ^xiru N          N '\___ H         I / X N N X-or any of its pharmaceutically acceptable salt.

32. Use of a compound of formula (Ia), (Ib) and (Id) as defined in claim14 or any of its pharmaceutically acceptable salts, and any of compounds (3) to (18), (32) to (35), (91) to (122) as defined in claim 13 or any of its pharmaceutically acceptable salts, in the manufacture of a medicament.2019300101   22 Jun 202633. Use according to claim 31 with the exclusion of compounds No 1 and2, as well as their pharmaceutically acceptable salts.